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Abstract of Thesis 
Introduction
Acute Pancreatitis (AP) is associated with a significant mortaiity despite advances 
in critical care and siu’gical management of the disease. A significant subgroup of 
patients with AP will have complications including Multiple Organ Dysfimction 
Syndrome (MODS) and Infected Pancreatic Necrosis (IPN) which are associated 
with higher mortality rates. The pathophysiology of MODS is not yet fully 
understood but cytokines are known to play a role.
Tiiree factors influencing mortality in patients with acute pancreatitis have been 
identified. Firstly, the host response to acute inflammation, wliich determines the 
pattern of cytokine response and may be subject to genetic control.
Secondly, the development of infected pancreatic necrosis and the influence of 
surgical strategies developed to deal with this. Thirdly, the nature of mfecting 
organisms in patients with IPN.
Aims
The aims of this thesis ar e
1) To compare genetic polymorphisms in an interleukin-8 locus in a cohort of 
patients with AP and healthy controls with regard to severity and susceptibility
2) To examine a retrospective series of patients with mfected pancreatic necrosis 
and compare open and percutaneous necrosectomy techniques with regard to organ 
dysfunction and mortality
3) To identify microbiological factors wliich may affect outcome in patients with 
infected pancreatic necrosis
1) Materials and Methods
Previously collected DNA samples from 106 patients with predicted severe AP 
were subjected to sequence specific PCR of 6 Interleukin-8 single nucleotide 
polymorphisms (SNPs) and compared with 100 healthy control DNA samples. SNP 
frequencies were compared in patients ivith mild and severe disease and between 
patients and controls.
Patients and Methods
2) Ninety-nine patients with infected pancreatic necrosis treated surgically at GRI 
between December 1989 and March 2002 were prospectively identified. 
Retrospective case note review was performed. Patients were divided into OPEN 
and PERC (percutaneous) groups for analysis. Outcome measui'es included 
mortality and ITU requirements.
3) The same IPN cohort was firrther analysed with respect to microbial spectrum, 
use of prophylactic antibiotics, development of resistant organisms and effect on 
mortality.
Results
1) No differences m Interleukin-8 SNP frequencies were noted between mild and 
severe patients or between patients and controls.
2) Fifty-six and 49 patients underwent open and percutaneous pancreatic 
necrosectomy respectively. Mortality rates were similar in both groups. 
Significantly fewer patients in the PERC group required ICU post-operatively 
indicating a reduction in post-operative MODS.
3) The spectrum of microbial infection varied slightly over the study period. 
Prophylactic antibiotic usage has been avoided latterly in this unit but overall 
prophylactic antibiotic use has not changed significantly.
Fungal infection was associated with higher mortality rates.
Conclusions
Several factors affecting severity have been identified in Acute Pancreatitis.
From this work, it has been demonstrated that:
1) Six Interleukin-8 polymorpliisms do not seem to be related to disease severity or 
susceptibility in a cohort of AP patients
2) Minimally invasive pancreatic necrosectomy reduces post-operative MODS in 
patients with IPN and may improve mortality with continued improvements in 
technique.
3) Fungal infection is associated with higher mortality rates in patients with IPN.
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Chapter 1
1.1 Acute Pancreatitis; General Introduction
1.1.1 Epidemiology of Acute Pancreatitis
Acute pancreatitis is a common cause of presentation to general surgical 
departments. The incidence of acute pancreatitis has increased markedly over the 
last 4 decades and appears to be rising (1).A retrospective analysis of all patients 
discharged from hospital with a diagnosis of acute pancreatitis m Scotland from 
1961 to 1985 showed an eleven-fold increase in the number of men with the 
disease. In female patients this was less marked with only a four-fold increase in 
incidence(2). Despite this large increase, mainly in young and middle-aged males 
and elderly females, there was no associated rise in mortality rates. The apparent 
increase in incidence was attributed to improved diagnosis and earlier awareness of 
the disease.
A further study analysed the same stable Scottish population between 1984 and 
1995. It demonstrated an increased incidence from 258 to 419 cases/million 
population with a similar trend in both men and women(3). The rise m younger 
females with the disease may be attributed to increased alcohol consumption.
The incidence in Scotland appears to be higher than in other UK regions. The 
liighest incidence of first attacks of AP in the Bristol area between 1968 and 1979 
was 111 cases/million compared with over double that figure in a smaller Scottish 
study 4 years later (4,5).
Tire proportion of alcohol related pancreatitis was also higher in Scotland. Alcohol 
accounted for 26% of attacks in Scottish men (15% overall) compared with 9% of 
men in the Bristol study. In a recent prospective multi-centre Italian study, only 
8.5% of patients had acute pancreatitis in association with alcohol(6).
19
1.1.2 Mortality Rates in Acute Pancreatitis
Despite advances in the management of acute pancreatitis, mortality rates seem to 
have stabilised at approximately 8% of all cases. In a retrospective study in 
Southern England, standardised case mortality rates compared with the general 
population did not change since the 1970’s, despite a doubling of hospital 
admission rates(l). In the latest Scottish national audit, the in-hospital mortality 
rate showed a slight reduction during the period 1984 toi 995 from 9% to 7.5% of 
all cases(3). Interestingly, the proportion of early deatlis did not change during this 
period and accounted for up to 60% of deaths.
1.1.3 Clinical features of Acute Pancreatitis
Most patients have a mild, self-limiting cour se and recover with simple supportive 
management. However approximately 20% of patients have a more protracted 
course associated with multiple organ dysfunction (MODS) and up to 50% of these 
patients die(3).
Patients classically present with a recent onset of upper abdommal pam, often 
radiating through to the back and fr equently accompanied by vomiting. Epigastric 
or diffuse tenderness is common and is often mistaken as peritonitis. Very rarely, 
abdominal wall bruising may be seen in severe cases. Dehydration is commonly 
seen on admission as a result of significant fluid depletion secondary to fluid shifts 
from the mtravascular component.
Patients often exhibit signs of fever, tachycardia and tachypnoea. In patients with 
organ dysfunction, hypotension, respiratory impairment, oliguria and mental 
impairment may be seen. The rmderlying pathophysiology effecting these changes 
will be discussed later.
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1.1.4 Diagnosis of Acute Pancreatitis
The diagnosis is usually confirmed biochemically by the presence of a rise in sei-um 
amylase along with a compatible clinical picture. Hyperamylasaemia can be 
associated with other acute abdominal conditions; careful clinical evaluation is 
crucial. Serum amylase may be only mildly elevated in patients with a delayed 
presentation. Lipase has a longer half-life and is more specific in the diagnosis of 
AP, but is not always available in routine clinical practice. Where lipase can be 
measured, it is preferable to amylase for diagnosis(7).
Plain X-rays do not have a role in diagnosis, however Chest X-Rays provide an 
early indication of severity in the presence of a pleural effusion(8).
Computerised tomography (CT) is sometimes used when there is diagnostic 
uncertainty, particularly in atypical presentations, though it is more often used in 
determining extent of severity and evaluating complications.
1.1.5 Aetiology of Acute Pancreatitis
The two most common causes of acute pancreatitis ai*e gallstones and alcohol. 
Together, these account for between 50 and 70% of cases (9,10) depending on local 
alcohol consumption.
Other less common causes include iatrogenic (most commonly after ERCP), drug 
induced (steroids, thiazide diuretics), trauma, viral (mumps, coxsackie), pancreatic 
malignancy, hyperlipidaemia, hypercalcaemia, hereditary and other rarer causes. 
Idiopathic cases should not be attributed to more than 20% of patients(l 1).
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1.1.6 Initiation of Acute Pancreatitis
The mechanisms by which an aetiological stimulus initiates acute pancreatitis are 
not frilly understood. Evidence suggests that AP begins witliin pancreatic acinar 
cells(12) rather than periductal cells, a hypothesis that was proposed 
previously(13). Activation of trypsinogen to the active trypsin is a key event. 
Trypsin is involved hi the activation and deactivation of other inactive digestive 
pancreatic enzymes (zymogens) such as chymotrypsin, elastase, lipase and 
trypsinogen. In normal conditions this occurs in the duodenum. However, in acute 
pancreatitis, premature activation of trypsin followed by activation of zymogens 
may be an early initiating event, tliough this is controversial(14,15) and trypsin may 
be a protective factor(16).
Several theories have been proposed. One of these is the co-localisation hypothesis 
which suggests that intracellulai' zymogens come into inappropriate contact with 
lysosomal hydrolases (cathepsin B) resulting in intra-acinar zymogen 
activation(17). Alcohol may induce AP by either sensitising acinar cells to injury or 
stimulating the release of cholecystokinin( 16). With gallstone pancreatitis, the 
initiating mechanism seems to be pancreatic ductal obstruction, possibly leading to 
pancreatic duct hypertension, reflux of bile or pancreatic secretions, or pancreatic 
duct hypertension. These can in turn result in pancreatic duct injury and premature 
zymogen activation(18).
The precise details of the mechanisms involved in the initiation of AP are unclear 
but are the subject of ongoing research.
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1.1.7 Pathophysiology of Acute Pancreatitis; a summaiy
Whatever the initiating event, acute pancreatitis is the clinical outcome due to 
injuiy of the pancreatic parenchyma. As a result, pancreatic parenchyma is 
destroyed and an acute inflammatory response is initiated.
Polymorphonuclear leukocytes inflltrate perivascular pancreatic tissue, increased 
vascular permeability occurs, followed by margination and migration of 
neutrophils. Phagocytes and macrophages accumulate and further damage is caused 
by the production of fl-ee oxygen radicals. Ongoing inflammatory stimuli can lead 
to the development of en2yme-rich pancreatic ascites or the development of acute 
pancreatic collections. In more severe cases, necrosis of pancreatic par enchyma 
may occur.
The local inflammatory reaction precipitates a systemic inflammatory response by 
the involvement of a host of other cells including monocytes. These produce 
cytokines which have a key role in amplifying the inflammatory process and 
triggering a complex systemic inflammatory response. This involves a wide array 
of inflammatory mediators, and activates the complement, histamine, coagulation 
and bradykinin cascades(19).
As a result of excessive inflammatory activity, a systemic response is seen 
clinically and manifests as the Systemic Inflammatory Response Syndrome, 
evidenced by tachycardia, tachypnoea, pyrexia and a leukocytosis. If the 
inflammatory mediators driving this response domhiate and are not down-regulated 
by anti-inflammatory mediators, tliis can result in organ dysfunction, MODS and in 
severe cases may lead to death(20).
The development of MODS and the involvement of cytokines are key factors 
affecting the severity of acute pancreatitis and are the focus of investigation in this
23
current work. These concepts are discussed in more detail in later sections of this 
chapter.
1.2 Clinical Management of Acute Pancreatitis
1.2.1 Supportive management
The initial management of acute pancreatitis is essentially supportive. In the 
majority of mild cases, symptoms and clinical parameters improve within 3-5 days; 
restoration of oral fluid intake followed by diet is guided by symptoms.
Aggressive initial fluid resuscitation followed by adequate intravenous fluid 
replacement is important m mhiimising hypovolaemia, particularly in patients 
developing organ dysfunction. Inadequate fluid resuscitation in the early phase of 
AP may be a factor in the development of necrosis(21). Central venous pressure 
(CVP) monitoring may be required to optimise fluid replacement.
Assessment of respiratory function by peripheral oxygen satuiution monitoring and 
respiratory rate is beneficial and allows earlier detection of respiratory impairment. 
Oxygen saturation should be kept above 95%. Respiratory support consisting of 
supplementary inspired oxygen is required in patients with evidence of low oxygen 
saturation and/ or hypoxia on arterial blood sampling.
Adequate analgesia is prescribed according to the severity of pain.
The use of urinary catheterisation to monitor urine output, arterial lines for regular 
blood sampling, CVP measurement and NG tubes are frequent adjuncts in the 
management of these patients, particularly if there is any indication of a 
deterioration in the clinical condition.
24
In patients with MODS with evidence of renal and cardiac dysfunction, the addition 
of haemodialysis/haemofiltration and inotropic drugs to improve organ function 
may be required.
Although most patients do not present with evidence of organ failure, a significant 
proportion will develop this within the first week of admission. In a recent study in 
GWgow Royal Infirmary, 44% of predicted severe (APACHE II >6) patients 
developed early organ dysfimction with a subsequent 20% mortality (22,23), 
Therefore, initial assessment of severity is important and regular review is vital to 
identify and treat any deterioration in the patient’s condition as early as possible. 
The early recognition of complications including MODS allows timely use of High 
Dependency or Intensive Cai e units as appropriate. Referral to a specialist unit is 
indicated in patients with severe complications, particularly pancreatic necrosis of 
more than 30%(11).
1.2.2 Investigation of Acute Pancreatitis
Initial investigations include Serum amylase, FBC, U+Es, LFTs & CRP 
Arterial Blood sampling is useful in identifying hypoxia and acidosis.
Abdominal Ultrasound (US) has been established in clinical practice to determine 
the aetiology indicated by the presence of gallstones and should be performed early 
in the course of the illness(24). Up to 30% of patients with acute pancreatitis have 
no apparent aetiology, limiting optimal management and prevention of recurrence. 
Endoscopic US (EUS) techniques have developed in recent years and can be useful 
m detecting microlitliiasis in patients who have recrurent attacks(25).
Magnetic Retrograde Cholangio-Pancreatography (MRCP) has a role in identifying
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ductal abnormalities and can be used to further investigate patients with idiopathic 
AP as a significant proportion of these may have undiagnosed gallstones(26). 
Computerised Tomography (CT) is indicated on admission if there is diagnostic 
uncertainty. Dynamic contrast enhanced CT scanning (pancreatic protocol) is 
recommended in patients with ongoing symptoms and clinical evidence of sepsis a 
week after admission or in patients with deteriorating organ dysfunction(7).
It is also a useful modality in assessing disease severity and establisliing the 
presence of local complications such as pancreatic necrosis and acute fluid 
collections. In addition, CT findings can give some indication of prognosis(27). 
Pancreatic gas seen on CT scanning in association with necrosis is indicative of 
infection and requires definitive debridement.
CT guided Fine Needle Aspiration (FNA) is occasionally performed to exclude 
infection in patients with necrosis who have ongoing signs of sepsis, but should be 
used cautiously to avoid infection and other complications(7,28)
1.2.3 Nutrition
Maintenance of nutrition is an important aspect of management but remains 
controversial. Previously, it was considered essential to fast patients with AP m 
order to avoid further stimulation of the exocrine pancreas. Subsequently, the 
importance of maintaining nutrition was recognised and parenteral feeding became 
an important aspect of managing patients with severe AP.
Unfortunately the use of TPN in AP has been associated with infective and 
metabolic complications, possibly due to associated immune suppression and 
glucose intolerance(29). More recently, the role of the gut as a source of, and 
barrier to infection in patients with sepsis was recognised. Increased intestinal
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permeability occurs early and has been linked to bacterial translocation(30). hi 
addition pai'enteral nutrition has been identified as contributing to gut mucosal 
failure(3 l).Wlien compared with parenteral nutrition in 2 randomised trials, enteral 
feeding was found to be safer, cheaper and associated with less septic 
complications (32,33). Another study found enteral feeding associated with less 
organ failure, pancreatic necrosis and mortality than TPN(34). A Cochrane review 
in 2003 found inconclusive evidence of benefit associated with enteral feeding 
based on two randomised ti'ials(35). However, a more recent meta-analysis of six 
randomised studies showed reduced infection rates and hospital stay and 
recommended enteral feeding in AP(36).
Nasojejeunal feeding was initially recommended however more recent evidence 
suggests that naso-gastric feeding is as safe as nasojejeunal feeding and can be used 
in the majority of patients with AP(37,38). The latter is more teclmically 
demanding and requires additional endoscopic resources but is usefiil in managing 
patients with a degi'ee of gastric outlet obstruction due to duodenal compression 
horn pancreatic inflammation, collections or abscesses.
1.2.4 Management of Biliary pancreatitis
Gallstones account for up to 50% of cases of acute pancreatitis. US will detect the 
presence of gallstones in the majority. MRCP and EUS can be used to diagnose 
biliary pancreatitis if gallstones aie not detected on initial US. In patients with 
evidence of obstructive jaundice or cholangitis, ERCP and endoscopic 
spliincterotomy (ES) is recommended witliin 48 hours of admission or 72 hours 
from pain onset(7,39). In cases of gallstone pancreatitis without biliaiy sepsis or 
jaundice, the evidence regarding the benefit of early ERCP is contradictory. Two
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randomised studies have been performed comparing early ERCP with conventional 
management. Two of these showed a reduction in complications and in one a 
reduced hospital stay(40,41) and recommend ERCP in patients with severe or 
predicted severe biliary pancreatitis. However a later study did not show any 
benefit in early ERCP with increased complications in the patients who had 
ERCP(42). ERCP is routinely performed in patients witli evidence of biliar y sepsis 
and/ or obstiarctive jaundice but the use of ERCP outwith these indications depends 
on local practice. In elderly and unfit patients, there is a role for ERCP and 
prophylactic ES to avoid recurrent biliaiy pancreatitis where cholecystectomy is 
deemed high-risk(39). Cholecystectomy (open or laparoscopic with intra-operative 
cholangiogram) is recommended in patients with gallstone aetiology(43). In those 
with mild AP, tliis should ideally be performed within 2 weeks of discharge and 
preferably, within the same admission period. Patients with severe AP associated 
with MODS and / or necrosis should have delayed cholecystectomy to allow local 
and systemic inflammation to resolve(7).
1.2.5 Management of complications
Further management depends on the natural coui’se. Acute peri-pancreatic fluid 
collections occur in 30-50% of cases (44,45). These are often self-limiting and do 
not require intervention unless associated with obstruction or sepsis. In severe 
cases, local complications such as pancreatic necrosis are associated with higher 
mortality rates in association with MODS. The diagnosis of necrosis is based on 
correlation between deteriorating clinical condition and contrast-enhanced CT 
changes in pancreatic perfusion. CT is indicated if there is deterioration in the 
patient’s condition or evidence of sepsis. MODS is more likely in the presence of 
infection(46). Typically, infected pancreatic necrosis occurs in the 2”*^ or 3*^  ^week
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of illness. If infection is suspected, from clinical signs of sepsis and radiological 
evidence of gas or a necrotic collection, formal di'ainage by surgical, endoscopic or 
radiological methods is indicated(39).
Beyond the 5^ '^  week, pancreatic abscesses can develop. These are usually peri- 
pancreatic infected collections. They may develop in areas of necrosis or previous 
fluid collections. Compared with IPN, tliere is much less of an inflammatoiy 
response with fewer patients exhibiting MODS(47). Consequently, the mortality 
rate is significantly lower. Percutaneous or endoscopic drainage is often effective in 
their management(48).
1.2,6 Infected Pancreatic Necrosis
Infected pancreatic necrosis occurs in up to 10% of patients with acute pancreatitis.
It accounts for approximately half of deaths from acute pancreatitis in the UK and
is associated with mortality rates between 10 and 80%(49,50). IPN is often heralded
by a deterioration in the patient’s clinical condition, and may be suspected in
patients who develop recurrent or worsening organ dysfunction or SIRS. Blood
cultures can be helpful in identifying bacteraemia but are not diagnostic of IPN. CT
may be helpful as 20 to 55% of patients with IPN have gas noted on CT indicative
.of gas forming organisms (47,51). FNA may be performed in patients without CT 
evidence of infection in the face of continuing clinical suspicion of IPN. If FNA 
bacteriology is negative, it is usual to continue with conservative management. 
Consensus guidelines state that proven infected pancreatic necrosis in association 
with sepsis as a result of pancreatic infection is an indication for surgical treatment. 
High mortality rates for those with OD in association with IPN who are managed 
consei-vatively have been reported(2 0 ). Surgical management should include
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debridement or necrosectomy, and optimal post-operative removal of debris and 
exudates from the retroperitoneum(39). In those without MODS, some centres 
report success with conservative measures with either antibiotics or simple drainage 
as the only intervention(52). Other specialist centres have had success with CT 
guided drainage and continuous catheter lavage as the main method of controlling 
and treating the resulting sepsis(20). Endoscopic transgastric drainage has also been 
described but all of these studies report results in carefully selected patients, most 
of whom have little or no evidence of MODS.
Conventional surgical debridement has comprised laparotomy and open pancreatic 
necrosectomy. Debridement was previously chai'acteristically aggressive in keeping 
with basic surgical principles, multiple laparotomies were often required with 
associated high mortality rates. Open packmg was developed in the 1980’s with 
improved results(53). Intra and post-operative lavage have been added to open 
debridement procedures with variable results(54).
Patients imdergoing laparotomy for IPN are often critically ill with significant 
organ dysfunction and do not make ideal surgical candidates. Post-operative ITU 
care is usually required due to the severity of their clinical condition. Though 
mortality is high, it is generally recognised that to neglect to debride the necrotic 
tissue is to invite a much higher risk of death.
There has been a move in recent years towards less invasive techniques for 
drainage of necrotic material and pancreatic debridement.
Variation in techniques for sui'gical di'ainage of IPN will be discussed in a later 
chapter (Chapter 3).
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1.3 Role of Infection in Acute Pancreatitis
The optimal management of IPN includes surgical debridement or drainage of 
necrotic material as discussed above. In addition patients are commenced on 
intravenous antibiotics appropriate to the infecting organism and known 
sensitivities. Whilst the use of antibiotics in patients with IPN is an important 
adjunct in controlling sepsis, their use in patients without evidence of infection is 
controversial. Prophylactic antibiotics are often commenced in patients with MODS 
and with sterile necrosis. With increasing use of prophylactic antibiotics, the 
microbial spectrum of organisms found has shifted from predominantly gram- 
negative bacteria to gram-positive bacteria and fungi with an increased prevalence 
of antibiotic resistance in subsequently infected pancreatic tissue(55). Patients with 
resistant organisms had longer in-patient stays but mortality rates were not 
adversely affected. More recently, fungal infection has been associated with an 
increased mortality rate(56). The role of infection and the use of antibiotics in 
patients with IPN is discussed in greater depth in Chapter 4.
1.4 MODS and Acute Pancreatitis
1,4.1 Definition of MODS
The term Multiple Organ Dysfunction Syndrome (MODS) was proposed in 1992 at 
the American College of Chest Physicians and Society of Critical Care Consensus 
Conference(20) in order to better reflect the dynamic characteristics of this 
condition arising from various insults to the body. MODS was defined as the 
“presence of altered organ function in an acutely ill patient such that homeostasis 
cannot be maintained without intervention”
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Previously, the tenu “organ failui'e” was used widely but the definitions used varied 
considerably and made comparison between studies difficult.
1.4.2 SIRS
Tills conference also clarified the differences between the terms “septic syndrome” 
and “sepsis” which were often used interchangeably and incon'ectly in non- 
infectious inflammatory conditions. A new term “Systemic Inflammatoiy Response 
Syndrome” (SIRS) was recommended to reflect tliis response to a variety of clinical 
insults. This develops in patients with unregulated effects of pro-inflammatory 
mediators, clinically manifesting as tachycardia, hypothermia or pyrexia, 
tachyopnoea and a leukocytosis. These parameters can be objectively noted and are 
used to identify the presence of SIRS (Table 1.1). At this stage, either homeostasis 
can occur with improvement in the patient’s condition or further deterioration 
resulting in widespread organ dysfimction.
Table 1,1: Definition of SIRS
Clinical Parameter Criteria
Cardiac Pulse > 90/ min
Respiratory Respiratory rate> 20 or pC02>4.3kPA
Temperatuie <36‘^ cor>38“c
Inflammatoiy markers White Cell Count <40 or >120 (xlO^mm)
1.4.3 SIRS, MODS, CARS and MARS
Bone described the underlying pathophysiological mechanisms underpinning the 
progression horn SIRS to MODS in his hallmark paper in 1996(57).
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He proposed that the interaction between inflammatoiy and anti-inflammatory 
mediators resulted in several variations in response to a severe insult upon the body. 
In some patients, this response is down-regulated and although some organ 
dysfunction may manifest, this resolves quickly and the patient recovers. In these 
patients, pro-inflammatory mediators help to recruit other mediators such as 
neutrophils to the site of injury. These factors then stimulate anti-inflammatory 
mediators wliich oppose further pro-inflammatory activity and eventually restore 
homeostasis. In contrast, patients who have an overwhelming anti-inflammatory 
response continue to deteriorate and often this results in a fatal outcome. These 
patients initially demonstrate SIRS and progress clinically towards MODS. A 
compensatory anti-inflammatory response is initiated (CARS) which can be as 
extreme as the pro-inflammatory response. CARS is characterised by a period of 
anergy and marked immimosuppression. During tliis stage, patients aie at increased 
risk of infection, which if  occurs, acts as a fuither insult on an already weakened 
system and provokes a second anti-inflammatory response. A mixed inflammatory 
response (MARS) is seen where neither SIRS nor CARS predominate.
Persistent inflammation, persistent immunosuppression or a combination of both 
responses results in “immunologic dissonance” which has been described by Bone 
as “a pathophysiologic response that is out of balance and inappropriate for the 
patient’s biological needs”. Organ failure eventually occurs followed soon after by 
death unless homeostasis can be restored.
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1.4.4 SIRS and MODS in the development of Acute Pancreatitis
Although this pathophysiological description relates to MODS occurring from a 
wide variety of insults such as trauma, bums and severe infection, it is highly 
applicable to MODS occurring in association with acute pancreatitis (Figurel .1).
~a
IPN
sepsis
SIRSPrimary
MODS
Secondary
MODS
DEATHO U T C O M E
Cytokines
Figure 1.1: SIRS To MODS (adapted from (20))
Several possible clinical manifestations occur as a result of a combination of local 
and systemic inflammatory responses.
1 ) Pro-inflammatory mediators are balanced locally and homeostasis is 
restored, this is seen in mild cases of AP.
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2 ) SIRS develops but is balanced by CARS and homeostasis is restored, in 
patients with mild AP but with SIRS noted initially
3) SIRS predominates and progresses to MODS. This may be transient due to 
subsequent CARS and resolves within a short period of time.
4) SIRS predominates progressing to persistent MODS that is not down- 
regulated by CARS. Immunologic dissonance and death may follow. This 
may be seen in patients with early mortality secondaiy to MODS
5) MARS can occur and lead to local cell death (apoptosis) without much 
evidence of inflammation. This may be seen in patients with sterile necrosis 
and no MODS. Inflammation is balanced and these patients have a good 
prognosis.
6 ) MARS occurring with persistent MODS in addition to CARS results in 
immunosuppression and in the presence of pancreatic apoptosis predisposes 
to infection in the form of infected pancreatic necrosis. These patients have 
a much higher risk of death if MODS persists
7) MARS resulting in initial MODS followed by IPN. Surgical stress either 
stimulates a further episode of MODS leading to death, or helps to down- 
regulate the SIRS response leading to resolution and recovery.
1.4.5 MODS and Mortality in Acute Pancreatitis 
Early Deteriorating MODS
The Atlanta Symposium in 1992 defined severe AP in terms of patients with 
evidence of organ failure and / or local complications such as necrosis, pseudocyst 
and abscess formation(58).
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A recent prospective study analysed the relationship between early MODS and 
mortality in patients with predicted severe AP(23). It showed that patients with 
deteriorating early organ dysfunction had an associated mortality rate of 55%, 
compared with almost zero mortality in patients with early resolving MODS 
(p<0.001). Based on these findings, the study concluded that it is patients with 
deteriorating MODS that should be characterised as having severe AP, as patients 
with transient MODS usually recover and have low mortality rates. This contradicts 
the Atlanta definition which was based on the presence of MODS rather than the 
dynamics of the condition. Further studies have confirmed this observation and 
shown persisting organ failure to be the important adverse factor(59,60).
Those with transient organ dysfunction which improves within 48 hours, although 
satisfying the Atlanta criteria for severe AP are not at increased risk of dying and 
should not be considered as having severe AP. Tliis proposal was recently 
incorporated within UK guidelines on the management of AP(7).
Biphasic pattern and mortality rates
Acute Pancreatitis is associated with an overall mortality of 5-10%(3,61). Tliis 
tends to occur in a biphasic pattern. Early mortality in the first week is due to 
overwhelming Multiple Organ Dysfunction Syndrome (3). Those wiüi early MODS 
who survive the first week either recover or continue to have organ failiue. Septic 
complications occurring diuing or after the second week can trigger a fiuther 
episode of MODS in those who have recovered, or worsening MODS in those who 
continue to have organ failure and is known as the “second hit”. This may be fatal 
and is responsible for the majority of deaths seen in the third week and beyond (2 2 ). 
Patients with MODS have a much higher mortality rate than those who have no 
organ dysfunction tliroughout their illness. In patients who die, the proportion
36
attributed to early MODS has been shown in several earlier studies to be as high as 
60% (3).
This is in contrast to a prospective London audit which attributed only 32% of 
overall mortality to early M0DS(61). More recently, it has been proposed that 
mortality rates from early MODS may be decreasing, possibly due to advances in 
supportive therapy in the initial period of hospitalisation(62), though wide 
variations in early mortality rates from between 4-85% of all deaths are reported in 
different centres globally(50,63). This apparently large variation may be due to 
differences in patient populations and medical care proidsion.
Several studies have shown that the presence of organ dysfunction alone is a major 
determinant of mortality. A retrospective analysis of 267 consecutive patients in the 
Netherlands with acute pancreatitis showed an overall mortality of 19% with 96% 
of deaths attributable to multiple organ failure(64). This relationship has been 
demonstrated in several studies since. A Chinese retrospective analysis of 74 
patients with SAP showed a significant association between organ failure and 
mortality with a greater association between multiple organ failure and 
mortality(65). Other studies have confirmed a significant correlation between organ 
dysfunction and death(6 6 ).
At presentation, it can be difficult to predict clinically which patients fall hito the 
high-risk group that will develop MODS. Several scoring systems have been 
developed in an attempt to stratify patients into mild and severe groups and these 
are discussed below.
37
1.4.6 Assessment and Prediction of MODS 
Multiple factor scoring systems
It is important to be able to stratify patients into those likely to develop severe AP 
and the majority of AP patients who will have a mild, self-limiting illness(67). This 
enables early identification of patients who would benefit from specialist unit input 
and early intervention. In addition, it allows comparison of results in different units 
and identifies higher risk patients who may be suitable for recruitment into clinical 
studies. Over the last 3 decades, several multiple-factor scoring systems have been 
developed. The Ranson and modified Glasgow scores were developed in the 1970’s 
and early 1980’s and could predict severity with a sensitivity of up to 60% within 
48 hours of admission(68,69). (Appendix 1&2)
APACHE II Score
More recently, the APACHE II score was developed and though used initially for 
ICU patients to predict outcome, found widespread use m research settings in the 
1990’s for patients with AP to predict those more likely to have a severe illness. It 
was first described in 1985 and uses multiple physiological and laboratory 
parameters to provide a numerical score relating to severity of illness(79). Although 
the APACHE II score can be more complex to calculate, it can be used within the 
first 24 hours of admission. When compared with Ranson and modified Glasgow 
scores, it was found to be more accurate in a number of prospective studies(71-73). 
The cut-off score can be altered with a subsequent change in sensitivity and 
positive-predictive value (though a value of 6  can easily be achieved in the elderly 
with little physiological derangement). APACHE II scores with a minimum cut-off 
of 6-10 points have shown a positive correlation with a severe outcome(74).
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Other Predictive Factors
Simple clinical factors such as gi'eater age (over 70) and obesity are now well 
recognised as being important risk factors for severe AP. A recent modification of 
the APACHE-II score to include obesity was proposed as it provides greater 
accuracy (85%) when compared to APACHE ÏI alone(75).
C-Reactive Protein (CRP) has been most widely accepted for clinical practice. Its 
production by the liver is stimulated by Interleukin-6  and peak levels occur 46-96 
hours after onset of symptoms. It is not specific to acute pancreatitis but is simple 
and cheap to assess and has been adopted widely as an adjimct in assessing 
severity, it can indicate resolution of inflammation as well as indicating further 
inflammation and/ or necrosis.
Several other factors for assessing severity have been used in research settings and 
aie not available widely. These will not be discussed further here but include 
Trypsinogen Activation Peptide (TAP), Amyloid A, TNFa, Interleukin-6 , 
Interleukin-8 and Procalcitonin(76).
1.4.7 Quantification of MODS 
Marshall Score
The Marshall organ dysfunction score was initially described in 1995 for critical 
care patients and allocates a numerical value to the level of dysfunction noted in 
cardiovascular, renal, respiratory, neurological, hepatic and haematological 
systems(77). It was further modified by Bernard to exclude hepatic failure(78). This 
scoring system has been used extensively in more recent years in clinical trials of 
patients with AP. A modified Marshall score of 2 or more in any organ system
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correlates very closely to the definitions for organ failure as described at the Atlanta 
symposium (Table 1.2 and Figure 1.2).
Persistent or deteriorating Marshall scores of >2 in any one organ system is 
significantly associated with a Ingher mortality rate in patients with AP(23).
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Table 1.2:Marshall Score of Organ Dysfimction
0 1 2 3 4
Respiratory 
P02/ Fi02 ratio
>300 226-300 151-225 76-150 <76
Renal
Serum Creatinine
< 1 0 0 1 0 1 -2 0 0 201-350 351-500 >500
Hepatic
Serum Bilirubin
< 2 0 21-60 61-120 121-240 >240
Cardiovascular 
Pressure adjusted 
heart rate
< 1 0 10.1-15 15.1-20 20.1-30 >30
Haematological
Platelets
> 1 2 0 81-120 51-80 21-50 <20
Neurological
GCS
15 13-14 10-12 7-9 < 6
1 ) Tliree or more Ranson criteria
2) Eight or more APACHE II points
3) Organ failure defined as follows; Shock: Systolic BP <90mmHg
Pulmonary Insufficiency:PaO2<60mmHg 
Renal Failure: Creatinine level> 170umol/L 
GI Bleeding: >500ml/24 hours 
DIG: platelets<100(lxl0mm6)/ Fib <lg/L 
Severe metabolic disturbance e.g. hypocalcaemia
Figure 1.2 Atlanta criteria for Severe AP
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1.5 The Role of Cytokines
1.5.1 General introduction to Cytokines
Cytokines are soluble chemical messengers of low molecular weight which are 
produced to facilitate cellular communication, including interaction between APC, 
T-helper cells and B cells. Chemokines are a subgroup of cytokines which have 4 
characteristic cysteine residues within their structure(79.
The most common sources of cytokines include monocytes, macrophages, T-Helper 
cells, granulocytes and endothelium. Cytokines are continually being discovered 
and despite having distinct protein structmes and sometimes opposing biological 
activity profiles, they share a number of properties. Cytokines exhibit pleiotropism 
whereby they can each act upon different types of target cells. Conversely, different 
cytokines can exert similar biological effects through their interaction with specific 
target cell surface receptors. This in turn activates intracellular synthesis of new 
mRNA followed by new protein production(80). By this method, cytokines are able 
to induce increased self-production as well as increasing production of other 
cytokines. This process is termed amplification and leads to the development of a 
cascade of cytokine-driven effects. Many have both autocrine and paracrme 
functions. Cytokines play an important role in regulation and activation of the 
immune and inflammatory responses by controlling humeral and cellulai* 
activity(Sl). They are produced rapidly by their cell of origin upon recognition of 
antigenic substances such as bacterial endotoxin or tissue injury. Each cytokine is 
produced specifically in response to a particular stimulus. They are involved in a 
wide range of acute and chronic inflammatory conditions (82) and have also been 
implicated in the development of neoplastic processes.
42
1.5.2 Cytokines and the Inflammatory Response
Cytokines are some of the principle mediators of the pathophysiological processes 
underlying SIRS and the development of MODS. These have been discussed 
previously in terms of their clinical manifestations. On a cellular level, cytokines 
are released as part of the body’s normal response to infection and/or injuiy. The 
inflammatory cascade aims to eradicate any invading organisms and repair any 
tissue damage that has occurred. This is achieved by a variety of cellular 
mechanisms including the division of stem cells and activation of lymphocytes, 
macrophages and phagocytes. T cells, B cells and platelets are recruited. Migration 
and margination of neutropliils occurs along with extravasation of monocytes. 
These in turn, produce more pro-inflammatoiy cytokines, principally TNF, IL-1 
and IL-6 . Fluid exudation occurs as a result of increased vascular permeability. 
Activation of the complement, coagulation, histamine and bradykinin systems 
occurs which further amplify the inflammatory response(83).
There is accumulating evidence to suggest that it is the local production of 
inflammatoiy mediators in response to a specific insult, whether it be infection, 
trauma, bums, ischaemia or organ damage, that results in the systemic effects 
(Table 1.3)(84). If this inflammatory cascade, mediated by cytokines, is not well 
controlled, it results in a massive inflammatory reaction and leads to organ 
dysfunction(85;86). This has been discussed previously with respect to acute 
pancreatitis in terms of SIRS, MODS, CARS and MARS.
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Table 1,3 : Pathophysiological processes underlying SIRS (adapted from (87))
• Progressive endothelial dysfunction, increased microvascular 
permeability
• Platelet sludging blocks microcirculation, blood flow misdistribution 
+/- ischaemia
• Ischaemia may cause reperfusion injury
• Induction of heat shock proteins
• Coagulation system activation, impaired Protein C-Protein S pathway
Pro-inflamniatoi'y and antMnflammatoiy mediators
At the local site of injury or infection, the initial appearance of pro- and anti­
inflammatory mediators in the circulation are beneficial. Restoration of homeostasis 
is the ultimate aim of these responses. If the balance between pro- and anti­
inflammatory activity is lost, then these mediators become harmful.
This delicate balance between opposing natural forces was recognised almost 20 
years ago and likened to the traditional Chinese philosophy of “Yin and Yang” 
(8 8 ). This description remains valid for the interaction between pro- and anti- 
inflammatoiy cytokines.
Cytokines such as TNFa, interleukin-1, interleukin-6 , interleukin-8 and PAF are 
pro-inflammatory, resulting in priming and activation of neutrophils, increased 
macrophage activity and recruitment of B & T cells.
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They are opposed by anti-inflaminatoiy cytokines such as interleukin-1 receptor 
antagonist (Il-RA) and interleukin-10 (11-10) which inhibit T helper cell cytokine 
production and modify the inflammatory response.
Other cytokines are included below (Table 1.4)
Table 1.4: Pro-inflammatory and Anti-inflammatory Cytokines adapted from (87)
Pro-inflammatory Cytokines Anti-inflammatory cytokines
Tumour Necrosis Factor alpha (TNFa) Interleukin-1 receptor antagonist
Interleukin-lb Interleukin -4
Interleukin -2 Interleukin -10
Interleukin -6 Interleukin -13
Interleukin -8
Interleukin -15
Interleukin-18
Interferon gamma (IFN-y)
Platelet Activating Factor (PAF)
1.5.3 Role of Cytokines in Acute Pancreatitis.
Acute Pancreatitis progressing from localised pancreatic inflammation to a more 
generalised systemic disease in the form of SIRS and MODS is now recognised as 
being mediated by cytokines(89;90). Increasing evidence suggests that MODS in 
acute pancreatitis is associated with excessive pro-inflammatory cytokine 
action(91-93). The exact pathways by winch inflammatoiy mediators are triggered
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in acute pancreatitis and exert their remote effects are not yet completely 
understood but several cytokines have been implicated.
Tumour Necrosis Factor (TNF)
TNF was one of the first cytokines to be described. It is produced by several cells 
including macrophages, monocytes, mast cells and T cells and acts by increasing 
endothelial permeability and inducing other inflammatory mediators such as 
neutrophils, macrophages, interleukin-1 and Platelet Activating Factor (PAF).
TNFa (pro-inflammatoiy) and TNFp (anti-inflammatory) are both involved in 
modulating the inflammatory response. TNFa is secreted primarily by monocytes 
and is involved in the initial stages of pancreatic inflammation. It initiates 
production of cytokines including IL-6  and IL-8 . In an experimental model of AP, 
pancreatic acinar cells have been found to produce, release and respond to TNFa. 
Furthermore, neutralisation of TNFa resulted in reduced acinar cell apoptosis(94). 
In clinical studies, monocyte production of TNFa, IL-6  and IL-8  were significantly 
increased in AP patients with systemic complications compared to patients with a 
milder course(95), further implicating these cytokines as early mediators of the 
systemic effects of AP. Previous studies of TNFa plasma levels in AP patients had 
been mconclusive(96). This may be related to die short half-life of TNFa and its 
intermittent secretion, which together with infrequent samplmg, make assessment 
of plasma levels difficult to interpret (97). Instead soluble TNF receptors can be 
measured to reflect TNF activity.
The association between TNFa, and organ failure in acute pancreatitis was further 
demonstrated by significantly increased serum levels of soluble IN F receptors 
(sTNFss and STNF75) (98). Activated pancreatic enzymes, including elastase, have 
been shown to induce macrophages to produce TNFa through specific
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transmembrane receptors suggesting the mechanism by which TNF is produced in 
response to pancreatic damage(99). Pancreatic ascites has also been shown to 
induce TNFa and IL-1 (3 production, though the exact mechanism for this is 
unciear(lOO). TNFa blockade has been successful in significantly reducing the 
mortality rate associated with severe AP in an animal model of AP using a 
recombinant form of soluble Type ITNFa receptor. This effect was achieved by a 
reduction in inflammatory cytokhie production. In addition, attenuation of the 
severity of the disease was more effective when TNFa antagonism was delayed 
until circulating cytokine levels were high(lOl). No studies involving 
TNFa inhibition in humans have been carried out to date. The potential of anti- 
TNFa treatment is worth considering as a subject for future study.
Interleukin-l
This cytokine is similar to TNFa in its properties and wide range of action. It is an 
early inducer of tlie acute inflammatory response. Like TNF, it is difficult to 
measure in serum. It is antagonised by IL-1 receptor antagonist (IL-lra), measuring 
IL-lra reflects IL-1 activity more accurately.
Interleukin-6
This cytokine is involved in the acute phase response; it is a T cell derived cytokine 
and activates B cell differentiation. Raised plasma IL-6  has also been found in 
patients with severe disease and organ failure (98). IL-6  is a good marker of disease 
severity and elevated levels precede CRP elevation in the first 48 hours (102). 
Interleukin-8
The main role of IL-8  is in the recruitment and activation of neutrophils. In an early 
study of IL-8  and pancreatitis, plasma levels were higher in patients with 
complicated pancreatitis and correlated closely with neutrophil elastase (a marker
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of neutrophil activation) (89). Increased monocyte secretion of IL-8 has also been 
correlated positively with increased disease severity (92) adding further weight to 
IL-8 ’s role in the development of systemic complications in acute pancreatitis.
IL-8  & IL-6  plasma levels were found to reflect severity of AP in the first 24 hours 
with greater sensitivity than CRP, indicating their involvement in the early 
inflammatory response(103).
Anti-inflammatory Cytokines
Several anti-inflammatory cytokines have also been implicated in the development 
of severe acute pancreatitis.
Interleukin-10
hiterleukin-10 is produced by T helper cells, B cells, macrophages and 
kératinocytes. It is the principle anti-inflammatoi*y cytokine and down regulates the 
production of TNF, IL-1, IL-6  and IL-8  at a transcriptional level by inhibition of 
macrophages and T1-helper cells. In patients with severe AP, higher XL-10/ IL-6  
and IL-10/ IL-8  ratios were associated with improved clinical outcome despite 
elevated IL-10 plasma levels in these patients, suggesting that both pro- and anti- 
inflammatoiy cytokine activity is increased in severe AP (104). Further evidence of 
the role of IL-10 in modification of the inflammatory response comes from a study 
of ERCP patients. Exogenous IL-10 given prior to ERCP reduced the incidence of 
post-ERCP pancreatitis(105). In an animal model of SAP, human IL-10 gene 
administration resulted in significantly reduced mortality rates, histological changes 
and reduced tissue TNF levels (106).
IL-IRA, another anti-inflammatoiy cytokine, was administered to SAP induced 
mice with an associated reduction in mortality (101). In humans, cytokine 
inhibition in the form of Lexipafant, a potent inhibitor of PAF has been investigated
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in patients with predicted severe pancreatitis. PAF is released by activated 
monocytes, platelets and endothelial cells. It is involved in the pathophysiology of 
AP by activating platelets, monocytes and neutrophils in addition to increasing 
vascular permeability. Initial studies with Lexipafant showed some promise in 
reducing AP associated organ failure, though no change in mortality was noted 
(107). A later phase III multi-centre double-blinded trial did not confirm these 
findings in a larger group of patients (108),
1.5.4 The Role of Cytokine Genetics
There is significant individual variation in the cytokine response seen in a number 
of inflammatoiy and immime mediated conditions. There is increasing evidence 
that polymorphisms in cytokine gene loci are important determining factors 
affecting cytokine gene function with subsequent effects on disease susceptibility 
and severity,
A single Medline search for the term “cytokine gene polymorphisms” elicited 2397 
articles over the last 23 years. Obviously, not all of these have positive disease 
associations but the large number of studies indicates the interest in this area. 
Evidence suggests that variations in the genetic make-up of cytokines can affect 
their fimction (109), This could account for the variation seen in the regulation of 
the inflammatory response in individuals (110), There is increasing evidence to 
suggest that TNF polymorphisms are involved in susceptibility and severity in 
patients with sepsis. The TNFa —308A allele in particular has been implicated. It is 
associated with increased TNFa gene transcription, monocyte secretion and blood 
concentration levels (111). An association between TNFa -308 and mortality has 
been demonstrated in 98 British children with meningococcal sepsis (112). Further
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evidence of a relationship to sepsis is demonstrated in a French study of 89 ICU 
patients with septic shock, with a greater susceptibility to sepsis and mortality in 
patients with the -308A allele (113). This study did not stratify ethnicity which can 
be a confounding factor in genetic studies. However a similar association was seen 
in postoperative Asian patients with septic shock. Non-survivors were more likely 
to possess the -308A allelic variant (114). No association was noted in a German 
study comparing 80 post-operative patients with etlmicity-matched normal controls. 
They proposed tliat positive associations with sepsis and TNFa -308A may be due 
to linkage between this locus and another Major Histocompatibility (MHC) locus 
(115). A more recent study found that the TNFa-308A variant as well as a Toll-like 
receptor (TLR4) SNP were both associated with an increased risk of sepsis 
following burn trauma but not mortality(l 16). Although the evidence for the 
importance of the TNFa-308A allele is mounting, some studies have been 
inconclusive. This could be due to a number of reasons including study design 
deficiencies, and difficulty in interpretation as a result of background genetic 
variability (117). In acute pancreatitis, few cytokine gene polymorphisms have been 
studied with varying associations between polymorphic gene jfrequencies and the 
disease. In the TNF promoter region, 5 microsatellites (TNFa-e) and 2 SNP sites (- 
308, -238) have previously been identified (118). AlleleZ at the TNFa 
microsatellite has been associated with increased TNF production (119). Three of 
these TNF microsatellites (TNFa,b,c) and a SNP (-308 A/G) were typed in a 
population of AP patients and compared with normal controls. No differences in 
allelic frequencies were noted between mild and severe patients or patients and 
controls (120). However, in a series of 72 patients witli AP, TNFa-308A was more 
than twice as fiequent in patients with severe AP compared to those without (121).
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Ill another study, TNF —308 SNPs and TNFB microsateliite, IL-lb and IL-lRA 
were determined in 190 AP patients and compared with controls. No difference was 
noted in the TNF genotype frequencies, however, an imbalance between IL-b and 
XL-Ira secretion appears to exist in patients with severe AP. The genetic basis for 
this could not be explained. In a separate study by the same group, the interleukin-1 
gene cluster was compared in patients and controls. Allele 1 in the IL-IRN 
polymorphism (IL-1 receptor antagonist gene) was more frequent in patients with 
severe disease and more frequent in patients compared to controls. Allele 2 
corresponds to high IL-lra secretion; the authors proposed that Allele 1 therefore is 
associated with lower IL-lra secretion. This would support the hypothesis that by a 
reduction in IL-lra, there would be less anti-inflammatory activity and a subsequent 
increase in severity (122).
1.5.5 Investigation of an Interlenkin-8 Microsatellite
A microsatellite close to the interleukin-8  gene has been identified and is associated 
with susceptibility to panbronchiolitis (123). This microsateliite had not been 
investigated previously in patients with acute pancreatitis until recently. A study 
conducted at Glasgow Royal Infirmary explored this polymorphic microsateliite m 
the interleukin-8  genome in a population of 86  patients with acute pancreatitis (124) 
and compared allelic fr equencies in patients and controls. Allele 9 was significantly 
over-represented in patients with no organ dysfunction compared to those with 
early CD (p=0.006). Patients with allele 9 were found to be tliree times less likely 
to develop MODS during the course of acute pancreatitis when compared with 
other acute pancreatitis patients. These results thus proposed a protective element 
associated with allele 9. It is not fully known what the significance of tliis
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microsatellite is in relation to the functional expression of Interleukin-8  but as it 
located in the promoter region, it is possible that it exerts an influence on gene 
transcription/translation and thereby affects Interleukin-S production levels. No 
evidence exists however to demonstrate the mechanism by which this microsateliite 
influences Interleukin-8 function or production. A functional haplotype containing 
six SNPs has been described and is associated with increased Interleukin-8  
transcription (125,126). These SNPs have yet to be examined in patients with acute 
pancreatitis.
Why some individuals progress down a certain pathway of systemic inflammatory 
behaviour as a result of pancreatic inflammation is uncertain but may be due to 
inlierent genetic variation. If individual cytokine gene variations could be mapped 
out in relation to their inflammatory behaviour', then this would lead to a greater 
understanding of the precise mechanisms by which cytokines are produced and 
their role in the development of MODS. Further studies are needed to investigate 
the role of cytokine gene polymorphisms in the development of severe AP.
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1.6 Hypothesis
Acute Pancreatitis is a condition ranging in clinical severity from a mild 
uncomplicated illness to a severe, overwhelming disease involving multiple organ 
failure and in some, death. The difference in allelic frequency of an IL-8  
microsateliite between patients with severe and mild AP is the first evidence for the 
role of interleukin-8  genetic polymorphisms in the development of acute 
pancreatitis. Several single nucleotide polymorpliisms have been discovered in the 
interleukin-8  promoter gene locus (125). Their role in association with acute 
pancreatitis has not yet been explored. Patients frequently have MODS in 
association with infected pancreatic necrosis with a higher risk of mortality,
Surgeiy for IPN can precipitate a second inflammatoiy response resulting in further 
MODS and death in a proportion of patients. With the development of minimally 
invasive necrosectomy teclmiques, this may be associated with reduced surgical 
stress and a reduction in MODS and/ or mortality. These techniques have yet to be 
compared to conventional open necrosectomy procedures. Bacteriological profiles 
are important determinants of survival. The widespread use of prophylactic 
antibiotics has led to a change from predominantly gram-negative to gram-positive 
and resistant organisms. The change in microbial spectrum may be associated with 
higher mortality rates.
Several factors have been recognised as having a role in the development of MODS 
and influencing outcome in acute pancreatitis. The work of this thesis will be based 
on the following hypotheses:
1) Cytokines are a key factor in mediating the local and systemic inflammatoiy 
responses seen after the initiation of acute pancreatitis. Interleukin-8  single
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nucleotide polymorphisms me involved in the inter-individual variation in 
systemic response to acute pancreatitis
2) Minimally invasive pancreatic necrosectomy reduces the surgical stress 
response associated with infected pancreatic necrosis resulting in less ICU 
requirements and a lower mortality rate.
3) Increased use of prophylactic antibiotics in patients with MODS has 
chmiged the spectrum of microbial infection with increased fungal infection 
resulting in higher mortality rates.
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1.7 AIMS
This thesis aims to focus on tliree aspects which seem to be important in the 
development of Severe Acute Pancreatitis
1) Interleukin-8 is a cytokine involved in mediating the inflammatory response 
in acute pancreatitis. Genetic polymorphisms in the IL-8  locus have yet to 
be explored in patients with AP. The role of interleukin-8  in acute 
pancreatitis will be explored by assessing IL-8  polymorphisms in patients 
with mild and severe pancreatitis and comparing tlrem with a control 
population.
2) The influence of minimally invasive pancreatic necrosectomy on MODS in 
patients with infected pancreatic necrosis vrill be examined by comparing 
their outcomes with patients undergoing conventional open necrosectomy
3) The influence of prophylactic antibiotics in the development of resistant 
organisms and the effect on subsequent mortality will be explored further by 
assessing antibiotic use, infecting organisms and outcomes in a cohort of 
patients with IPN.
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Chapter 2 
Exploration of the influence of Interleukin-8 genetic 
polymorphisms on pancreatitis severity and susceptibility.
2.1 Introduction to Interleukin-8
2.1.1 Discovery of Interleukin-8
Interleukin-8  was first identified in 1987 as a novel type of neutrophil-activating 
chemokine and was known by a variety of terms such as “Human Monocyte- 
derived Neutrophil Chemotactic Factor (127) and was renamed “interleukin-8” in 
1989 (128). It belongs to a family of small, structurally related pro-inflammatoiy^ 
chemokines similar to Platelet factor 4 (129). To date over 50 chemokines have 
been discovered and are broadly divided into CC and CXC subfamilies depending 
on the position of the first two cysteine residues in relation to each other(129; 130). 
Chemokines play a major role in mobilising host defences by attracting and 
activating the cells of the immune system (131). Interleukin-8 is produced by T- 
helper cells, phagocytes and mesenchymal cells amongst others, in response to 
cellular injiuy from a variety of causes such as ischaemia, trauma and infection. 
The process of inflammation is the resulting host response and is characterised by 
the movement of neutrophil leukocytes to the site of injury in association with the 
extravasation of fluid. The main action of Interleukin-8 is to activate neutrophils 
and facilitate migration.
2.1.2 lnterieukin-8 Structure and Function
The stmctui’e of Interleukin-8  varies from a precursor of 99amino-acids to several 
biologically active foims, the most predominant of which exists as a 72amino~acid
!
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molecule containing 4 cystienes which form 2 disulphide bridges (129).
Interleukin-8 , along with most other chemokines, forms dimers, which dissociate 
upon dilution. The monomer constitutes the biologically active form (132).
Interleukin-8  is one of the main tissue-derived chemoattractants for neutrophils and 
exerts its effects in tliree ways(129). Firstly by neutrophil shape-change and 
directional migration. This occurs after activation of the contractile system of 
neutrophils, allowing a change in cell body volume thereby enabling neutrophils to |
adhere to endothelial cells and to migrate. Secondly, exocytosis of specific granules /
and storage vesicles with subsequent enzyme release (e.g. elastase). Interleukin-8  
dependant surface remodelling during exocytosis leads to the expression of 
adhesion molecules which enhance the neutrophil’s ability to adhere to endothelial ;
cells and the extracellular matrix. Thirdly, the "respiratory burst” involves the rapid 
and transient activation of hydrogen peroxide and superoxide radicals, a recognised 
characteristic of stimulated phagocytes. Interleukin-8 receptors exist in a variety of 
forms, with many acting as non-specific receptors. Interleukin-8  interacts vfith 
neutrophils by binding to two receptors on its surface, the chemokine receptors 
CXCRl and CXCR2. A specific receptor (IL-8-RA) has been identified.
2.1.3 Interleukm-8 Genetics
Interleukin-8  is known to have a large variation in expression levels. It’s production 
can be rapidly induced by a number of stimuli, including other pro-inflammatory 
cytokines such as TNF-1 and IL-1 which can result in secretion levels increasing up 
to 100-fold. Bacterial and viral products can induce up-regulation by 5-10 times 
(133). The gene for interleukin-8 production /secretion is located on Chromosme 
4q. Genetic polymorphisms account for different traits being expressed in humans
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and other organisms. Polymorphisms have also been associated with varied 
susceptibility to disease. A polymorphism is an allelic variant that occurs in >1% of 
the population, has a stable frequency and cannot be accoimted for by mutation. 
They can either involve single nucleotide polymorphisms (SNP) or a varied 
sequence of nucleotides (microsateliite). SNPs tend to remain together within genes 
during meiosis. SNP pairs or units tliat are linked together in this way are known as 
haplotypes. SNPs are in sequence with non-variable parts of the genome and are 
linked with other SNPs in that region. This phenomenon is known as linkage 
disequilibrium. Therefore if  a haplotype is associated with a differing disease 
outcome then it is not known which is the causal SNP and which is in linkage 
disequilibrium with the causal SNP. Polymorphisms can occur in the promoter or 
encoding parts of the gene and may alter tire structure and therefore, the function of 
the resulting protein. Patients with various diseases have been investigated to 
establish the possible relationships between disease susceptibility or severity and 
genetic polymorphisms within particular genes. Several SNPs and a microsateliite 
have been found in the Interleukin-8 gene locus.
2.1.4 Interleiikin-8 polymorphisms and Disease Association
Numerous studies have been carried out on interleukin-8 polymorphisms to 
investigate possible associations with disease severity and susceptibility in a wide 
range of inflammatory and neoplastic conditions. These studies are based primarily 
on the premise that interleukin-8 plays a key role in the pathophysiology of 
inflammation.
Several respiratory conditions have been studied and are associated with 
interleukin-8 polymorphisms. Diffiise panbronchiolitis is a chronic inflammatory
58
airway disease of unknown aetiology ehamcterised by inflammatory lesions with 
infiltration of lymphocytes and foamy macrophages around bronchioles as well as 
marked neutrophil accumulation. It is more common in Asian populations. Elevated 
interleukin-8 concentrations are found in the airways of patients with the 
disease(134). In 1999 a Japanese gi'oup discovered an association between a 
microsateliite at tlie interleukin-8 locus and diffuse panbronchiolitis(123). Of 9 
possible alleles, allele 2 was significantly over-represented in patients compared to 
controls suggesting increased susceptibility to the disease in these individuals. 
Interleukin-8 polymorphisms and susceptibility to respiratory infections was ftirther 
demonstrated by a recent study into Tuberculosis (135). Interleukin-8, not 
surprisingly, is known to be involved in the pathogenesis of TB. Ma and colleagues 
compared the genotypes of the -251A/T SNP in patients with TB compared with 
controls and found that homozygosity for -251A was significantly more 
predominant in patients. They also found that the -251A allele was preferentially 
transmitted to TB-infected children. This study adds further weight to the evidence 
of a relationship between IL-8 polymorphisms and susceptibility to TB.
The role of interleukin-8 polymorphisms in susceptibility to disease has been 
explored in patients with non-small cell lung cancer. Inflammation may play a key 
role in the development of lung cancer. A French group recently studied a variety 
of inflammatoiy-gene polymorphisms including COX-2, interleukin-6 and 
interleukin-8 and found that an IL-8 promoter polymorphism was protective in 
female subjects against the development of lung cancer(136). Other cancers have 
been studied with respect to inflammatoiy gene polymorphisms. The -251A SNP in 
the interleukin-8 gene has been shown to be associated with a reduced risk of 
colorectal cai’cinoma. (137). Another gastro-intestinal condition has also been
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linked with Interleukin-8 polymorphisms. Students travelling to Mexico for 5 
weeks were studied for symptoms of enteroaggregative Escherichia coli (EAEC) 
diarrhoea. Faecal Interleukin-8 levels were measured and the genotypes of 5 SNPs 
in the Interleukin-8 gene were identified. (138). Susceptibility to EAEC was more 
common in those with A/A and A/T genotypes at the (-251) locus compared with 
homozygous (-25IT). In addition, those with the AA genotype produced 
significantly greater quantities of faecal Interleukin-8. Tln ee novel interleukin-8 
polymorphisms have also been recently described in relation to severe systemic 
lupus erythematosus (SEE) nephritis (139). Allelic variations from the published 
sequence of a 1526 base pair segment of the Interleukin-8 5’-flanking region 
(between —57 and —1583 in relation to the tianslational start codon) were analysed 
in 162 healthy controls and 167 patients with SEE, of whom 120 had renal 
involvement. The novel SNPs are (-845C/T), (-738A/T) and (-353 A/T). This study 
found differences in the prevalence of SNP genotypes between healthy Caucasian 
and African-American individuals. The (-353A) allele was more dominant in 
African Americans. In addition, African American patients with severe SEE were 
found to have a significantly higher frequency of (-845C) compared to healthy 
African American individuals. The authors suggested that African-Americans with 
this polymorphism were more susceptible to severe SEE nepiiritis perhaps by an 
influence on IL-8 gene expression.
As discussed above, a Japanese group have previously described an over­
representation of allele 2 in a microsateliite close to the IL-8 gene in patients with 
diffuse panbroncliiolitis. Tliey proposed that this polymorphism was associated 
with increased susceptibility to the disease(123). This microsateliite was 
investigated in patients with AP. Allele 9 was more frequent in patients without
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organ dysfunction, suggesting a protective effect(124). However the role of tliis 
microsateliite in relation to the functional expression of Interleukin-8 is not known 
Interleukin-8 is also implicated in the pathogenesis of RSV bronchiolitis. It is 
produced by bronchial epithelial cells (140) after infection with RSV. Disease 
severity correlates with IL-8 mRNA levels in nasal secretions (141). Hull described 
six single nucleotide polymorphisms in the promoter region of the Interleukin-8 
locus and found an association between increased susceptibility to RSV 
bronchiolitis and six SNPs (-1722delT/ -251 A/ +3960/ +781T/ +1633T/ +2767T) 
(125). Furthermore these haplotypes were found to exist in almost perfect linkage 
disequilibrium. The SNPs described are found within the interleukin-8 promoter 
region and are titled according to the number of bases upstream fr om the start 
codon. Further work by this group suggests tliat tlie mechanism for disease 
susceptibility to RSV-induced bronchiolitis may be thi’ough a haplotype-specific 
increase in interleukin-8 transcription involving significant differential binding at 
the +781 T/C polymorphism (126). This functional Interleukin-8 haplotype has yet 
to be studied in patients with acute pancreatitis.
61
2.2 Hypothesis
Polymorphisms within the interleukin-8 gene locus have been associated with 
several infective, inflammatory and neoplastic diseases in terms of disease severity 
and susceptibility. A known microsateliite in the promoter region of the has been 
associated with the development of MODS in acute pancreatitis.
Other interleukin-8 polymorphisms seem to be related to the functional expression 
of interleukin-8 and may in turn have an influence on the development of MODS in 
patients with acute pancreatitis.
2.3 Aims
1) To investigate six known single nucleotide polymorphisms in the 
interleukin-8 locus in a cohort of patients with acute pancreatitis and relate 
polymorphism frequencies to severity of pancreatitis.
2) To compare these six SNP’s frequencies in patients with acute pancreatitis 
witli SNP frequency in a healthy control population to examine 
susceptibility.
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2.4 Investigation of six lnterleukin-8 polymorphisms in patients 
with acute pancreatitis
2.4.1 Introduction
Polymorphisms within the interleukin-8 locus have been associated with many 
diseases with an inflammatory component.
Several SNPs have been described in the IL-8 promoter region but have not been 
assessed in patients with acute pancreatitis. Investigation of six interleukin-8 single 
nucleotide polymorphisms in patients with acute pancreatitis may provide further 
insight into the mechanisms by which interleukin-8 functions. A greater 
understanding of the influence of genetic factors on cytokine function and outcome 
in acute pancreatitis may be reached. The interleukin-8 locus is represented 
showing the relative SNP positions within the locus (Figure 2.1).
Interleukin-8 Gene
Exon 1
5 '  P rom ote r  
region
Intron 1
E xon 2 Exon 3 E xon 4
Intron 2 Intron 3
ntron 2 nlron 3Intron 1no te r
reg on
+396 +781
U ntranslated
\
+2767
Single Nucleot ide  Po lym orph ism s
Figure 2.1 Interleukin 8 Gene Locus
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2.4.2 Methods 
A: Materials and Methods 
Polymerase Chain Reaction (PCR)
This technique allows a specific sequence of DNA to be amplified. It was first 
described in 1974 (142). The basic principle of PCR involves two segments of 
short-stranded DNA (primers), which are complementaiy to opposing strands of the 
DNA segment of interest. Heating the reaction mixture allows dénaturation of the 
template DNA as well as binding primers to their respective template DNA 
sequences (annealing), followed by the synthesis of a complementary strand 
(extension) in the 5’ to 3’ direction. One cycle includes one roimd of dénaturation, 
annealing and extension and theoretically doubles the amount of template DNA. 
Several cycles of this process occur successively until an “amplification plateau” is 
reached after reaction reagents are depleted. The reaction temperature is extremely 
important and each step has an optimum temperature. This can vary for each stage 
of the PCR process (143). PCR is often performed in a thermal cycler which can 
automatically change the reaction temperature for specific lengths of time as well as 
the optimum number of cycles within each step. After 20 cycles, over a million 
copies of the template DNA ai'e synthesised.
DNA Extraction
DNA can be extracted firom a number of sources including peripheral blood, fresh 
tissue, hair, nail as well as archived material. Samples are incubated with Proteinase 
K for improved DNA quality. This is inactivated at the end of extraction by heat 
treatment. The DNA is purified using phenol chloroform in a number of extraction 
steps. The purified DNA is then suspended in a storage medium, which can either 
be a buffer or sterile distilled water.
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Optimisation of Reaction Conditions
Before carrying out PCR analysis, it is advisable to assess the optimal conditions 
for each reaction. Primers should range from 15-30 bases in length and consist of 
50-60% guanine and cytosine bases. Primer melting temperatures should be 
between 55-58 preferably. Annealing temperatures depend on the length of the 
primers as well as their composition and tend to be between 1-5^C lower than the 
lowest primer melting temperatures. If the annealing temperature is too low, then 
non-specific annealing and amplification can occur. If it is too high then PCR 
products are reduced.
Setting up PCR
The reaction mixture generally contains dNTPs (building blocks for DNA 
synthesis), test primers, control primers, Taq polymerase (catalytic DNA 
polymerase), as well as magnesium (stabilises the other components) and water (de­
ionised) to make up tlie volume to either 50 or lOOpl. The reagents aie placed in 
0.5ml tubes and placed in a thermal cycler programmed with the appropriate 
temperatures as well as the required number of cycles. The initial step involves an 
extended dénaturation period to allow template DNA strand separation. At the end 
of the reaction there is a final extension step at 72 °C degrees to ensure that all 
template DNA is double -stranded.
Validation of DNA
Included within the PCR reaction is another set of primers (controls) which 
amplifiy a known sequence within the genome. This ensures that the PCR reaction 
process has been successful and negative test results can be counted as valid and 
not as a result of poor quality DNA.
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Detection of PCR Products
The PCR products can then be viewed by gel electrophoresis. This process 
sepai'ates out differently sized DNA fragments. Gel electrophoresis is performed 
using an agarose gel (1-2%) usually containing Ethidium Bromide.
To determine polymorphic genotypes, 2 reactions are set up for each DNA sample, 
containing a different upstream primer. If the alleles are present then this will be 
viewed on the gel, if not, absent bands denote absence of that particular allele, 
when the SNP will be homozygotic 
B: Patients and Methods
Patients with a diagnosis of acute pancreatitis were recruited on the basis of clinical 
presentation and hyperamylasaemia. In order to obtain a cohort with a higher risk of 
organ dysfrmction, APACHE II scores were calculated on admission. Those with a 
score of 6 or more were included. Organ dysfunction was recorded daily as well as 
outcome. Patients were divided into two groups depending on severity of the 
illness. Those in the severe group had persisting MODS with a Marshall score of 2 
or over in one or more organ/system for 48 hours or more. All other patients were 
categorised as having mild acute pancreatitis. Peripheral venous blood was obtained 
from patients at the time of initial recruitment and refrigerated at 4^C. Ethical 
committee approval was obtained. DNA from 100 healthy donors from the regional 
tissue-typing laboratory was obtained.
Patient DNA
DNA was extracted from peripheral venous blood samples taken from patients at 
the time of initial recruitment to the study
DNA samples were subjected to optical density analysis using a spectrophotometer 
in order to make up DNA samples to a standard concentration of 50ng/pl.
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Control DNA
DNA taken from 100 West of Scotland healthy controls was used. These were 
selected randomly from a bank of samples maintained by the tissue-typing 
laboratory at Glasgow Royal Infirmary. DNA samples involved extmction from 
peripheral blood. The samples were from the same Caucasian population as the 
patients with acute pancreatitis. The samples were subjected to spectrophotometry 
to analyse optical density in order to confirm a DNA concentration of 50ng/pl. 
These DNA samples were novel to this work and had not been used in previous 
acute pancreatitis studies.
C: PCR reactions 
Primers
The oligonucleotide primers for the interleukin-8 single nucleotide polymorphisms 
were described by Hull. Six of the polymorphisms described were analysed;
-1722, -251, 396, 781, 1633, 2767 (Figure 1). Primers for these polymorphisms and 
control primers were synthesised by Holle & Hunter, UK (Figure 2.2).
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Figure 2.2: SNP segments and control primers.
Primer Name
-1722 del T 
-1722 ins T 
-1722 consensus 
-251 A 
-251 T
-251 consensus 
396 G 
396 T
396 consensus 
781 C 
781 T
781 consensus 
1633 C 
1633 T
1633 consensus 
2767 A 
2767 T
2767 consensus 
Control 63 
Control 64
Primer Sequence
5’ GTA AAA TAC AGT GAT GAG TGT TAC GAT AC 3’ 
5’ GTA AAA TAC AGT GAT GAG TGT TAC AAC AA 3’ 
5’ GTT GTG TCC ATA TGA GAA TGT GTC 3’
5’ CCA CAA TTT GGT GAA TTA TCA AT 3’
5’ CCA CAA TTT GGT GAA TTA TCA AA 3’
5’ TGC CCC TTC ACT CTG TTA AC 3’
5’ TTT ACG TTA AAT ATA TGC ATG TTA CC 3’
5’ TTT ACG TTA AAT ATA TGC ATG CTA CA 3’
5’ AAC ATG ACT TCC AAG CTG GC 3’
5’ TCA TAA CTG AC A ACA TTG AAC G 3’
5’ AGT CAT AAC TGA CAA CAT TGA ACA 3’
5’ TGA GTT GAG CAA GGT AAC TCA G 3’
5’ TAT GTA TGG TCT TTC TGG TCG TG 3’
5’ AAC TAT GTA TGG TCT TTC TGG TCG TA 3’
5’ GGA CTT AGA CTT TAT GCC TGA CTT AAG 3’
5’ CCC AGT TAA ATT TTC ATT TCA GAT AT 3’
5’ CCC AGT TAA ATT TTC ATT TCA GAT AA 3 ’
5’ GAC AAA CAC TTG ATT ACT TTG ACA ACA 3’
5’ TGC CAA GTG GAG CAC CCA A 3’
5’ GCA TCT TGC TCT GTG GAG AT 3’
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Optimisation of Sequence-specific SNP PCR Reactions.
Each SNP PCR reaction had to be optimised under different conditions including 
reagent concentration and annealing temperatures. Unless otherwise stated, 25 
annealing cycles were usually perfoimed.
The table below shows the different conditions that were explored for each SNP 
reaction (Table 2.1).
Table 2.1 : Optimisation of SNP reactions
MgClz Temp Temp Temp Temp Temp Temp
concentration S6°C 59T 60T 6UC 6 4T
(mM)
1
2.5 -251 weak +781 1633C
-251
5 1633 T +396weak +396
-1722
7.5
10 +2767A +2767T
Allele-specific PCR analysis
Each Interleukin-8 SNP genotype was determined in all patients and controls using 
the sequence specific Bioline protocol (Table 2.2).
Each downstream sequence specific primer (e.g. -251A and -25 IT) binds to their 
respective SNP bases along with the consensus upstream primer in both reactions.
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In order to have a positive control in each genotyping reaction, 2 other primers 
were designed which amplified a consensus region of the HLA-DRBl gene.
All six SNP experiments were carried out following a similar protocol (Table 2.2) 
based on the standard Bioline sequence-specific protocol, however some reagent 
concentrations and reaction temperatures varied depending on the optimal 
conditions needed for each reaction.
Table 2.2 Reagents and volumes (standard Bioline PCR Protocol)
Reagent Source Volume for one reaction
MgCl2 (2.5mM) Abgene, Surrey, UK 5 pi
Reaction Buffer IV xl Abgene, Surrey, UK 5pl
dNTPs (200uM) Abgene, Smrey, UK 5pl
Specific Primer 1 or 2 (200uM) Holle & Hunter, UK Ipl
Consensus Primer (200uM) Holle & Hunter, UK Ipl
Control Primer 63 (200uM) Holle & Hunter, UK Ipl
Control Primer 64 (200uM) Holle & Hunter, UK Ipl
Taq Enzyme Abgene, Suirey, UK 0.25pl
Sterile H20 28.75pl
Total Volume 50pl
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Sequence Specific PCR
Initially 4pl was taken from each sample of DNA and 2 pi placed into 2 separate 
1.5ml tubes.
One drop of paraffin and 48ul of master mix was added to each of the two tubes. 
The master mix was made up using a standard (Bioline PCR) protocol using the 
following; MgCh (2.5mM, Abgene), Buffer (Reaction Buffer IV x l, Abgene), 
DNTPs (200pM, (Abgene), specific primer l/2(200pM), consensus primer 
(20pOM), 63 control primer (200pM), 64 control primer (200pM), Taq enzyme 
(Bioline) (1.25) p and 28.751pof sterile water to make a total volume of p481. When 
added to the DNA in the reaction tubes, the total volume was 50pl (Table 2.2). 
Further specific controls using the tlnee possible genotypes were included with 
each experiment. Ionised DNA free H20 was used as a negative control. The 
samples were placed in a thermal cycler (Peltier PTC-225, MJ Research) and 
subjected to the following PCR reaction temperatures (Table 2.3); 4 cycles of 96,
35 secs; Temp (A), 45 secs; 72, 35 secs; 25 cycles of 96 (except for 781 SNP 
reaction), 25 secs; Temp (B), 50 secs; 72, 40 secs; 8 cycles of 96, 35 secs; Temp 
(C), 60 secs; 72, 90 secs with a holding temperature of IOC following this.
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Table 2.3: Reaction conditions for each sequence-specific PCR,
PCR MgCl2
(mM)
temp
(A)
No. temp 
cycles (B)
No. temp 
cycles (“C)
No.
cycles
-251 2.5 68 4 61 25 58 8
396 5 67 4 60 25 58 8
781 C 2.5 70 4 61 30 58 8
781 T 6 70 4 56 38 NA NA
1633 5 67 4 60 25 58 8
-1722 5 68 4 61 25 58 8
2767 A 10 67 4 60 25 58 8
2767 T 10 70 4 64 25 58 8
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Viewing PCR
The resulting PCR products were viewed using gel electrophoresis. A 2% agarose 
gel was made up using 2g of Agarose (Bioline), lOOmls of TAB buffer x l and 8pi 
of Ethidium Bromide and allowed to set for 30 minutes. One litre of Buffer solution 
was made up using 1 litre of TAE x l and SOpl of Ethidium Bromide. Wells were 
loaded with lOpl of PCR products from each tube (2 per DNA sample) and 5 pi of 
Orange G (company, made up) and run for 45 minutes at lOOVolts. A lOObase pair 
ladder (Hyperladder IV, Bioline) was placed in the last well of each row to size the 
resulting fragments approximately. The gel was then photographed (Sony 
Videographic printer. Genetic Research Instrumentation) under UV light 
(Transilluminator UVP, Germany) to identify the genotype bands (Figui'e 2.3)
Each patient’s genotype was then entered into a database (Microsoft Excel) for later 
analysis.
Unsuccessful samples
DNA samples that did not have genotype bands or had absent bands were subjected 
to 2 further PCR reactions m an attempt to try and characterise the DNA. DNA 
samples that remained unsuccessful were disregarded from the data collection and 
subsequent analysis.
Statistical Analysis
Patient genotype frequencies were compared with healthy controls using clii-square 
testing. Patients with mild and severe disease were also compared using chi-square. 
The two least prevalent genotypes were grouped together as dominant groups and 
were analysed using Fishers exact test.
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Figure 2.3 Gel Electrophoresis o f-251 PCR
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2.5 Results
106 patient samples were analysed, 2 of these had no successful genotypic bands 
with any of the six SNP assays.
Demographics
Table 2.4; Demographics of acute pancreatitis patients
Patients Gender Age median APACHE II Mortalit}^ (n=)
(SD) median (SD)
Mild 45M/41F 60 (SD 15) 9(SD 4.4) 2
Severe 12M/ 8F 65 (SD 17.9) 13.5 (SD 5.1) 13
All patients 57M/49F 60 (SD 15.6) 10 (SD 4.9) 15
Aetiology
Table 2.5: Aetiology in Acute Pancreatitis patients
Cause Mild Severe Total
n(%) n(%) n(%)
Gallstones 45 (52) 12 (60) 57 (53.7)
Alcohol 25 (29) 2 (KQ 27 (25.4)
ERCP 4 (4.6) 0 4 (3.7)
Other 12 (14) 6(30) 18 (16.9)
Although there is an observed preponderence of gallstones as the aetiology this 
approaches significance but does not reach it (p=0.1). If there were significantly 
more severe patients with gallstones as the aetiology, they would have to be 
investigated separately to avoid confounding factor bias.
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Unsuccessful samples
There was a significantly greater number of unsuccessful PCR reactions in the 
patient DNA samples compared with the control samples (29% v 8%)(Table 2.6) 
Table 2.6: Unsuccessful PCR samples
SNP Controls Mild Severe Total
-251 7 13 6 26
396 11 31 6 48
781 10 34 6 50
1633 4 35 5 44
1722 5 6 4 15
2767 9 29 7 54
Total 46 148 34 228
Mild and Severe
106 patients were analysed. Of these 20 patients had severe acute pancreatitis and 
86 had mild disease. The 2 DNA samples with no successful results were in the 
severe group. Of the remaining 18 severe patients, some individual SNP PCR 
assays were unsuccessfiil. Each patient’s results are shown with severe patients in 
bold type (Tables 2.7 & 2.8)
Patients and Controls
All six Interleukin-8 polymorphism assays were carried out on 106 patients and 100 
controls. The individual results aie shown (Tables 2.9 & 2.10)
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Table 2.1 \ Interleukin-8 SNP genotypes in Acute Pancreatitis patients
Patient Sample -1722 -251 396 781 1633 2767
3 TT TT
4 N oT TT
5 CT CC AT
6 NoT AA TT TT AA
8 N oT AA TT AA
9 N oT TT TT
12 N oT AT GT
13 TT CT CC AT
14 N oT AT GT CT AT
15 N oT CT AT
17 N oT TT
18 N oT AA TT TT AA
19 N oT CT TT AT
20 N oT CT CT AT
21 N oT CT CT AT
22 N oT
23 N oT AT
24 N oT AA TT TT AA
25 N oT TT CT CC
27 N oT AA TT TT
28 N oT AT TT TT
29 N oT AT CT AT
31 N oT AA GG
32 N oT AT GT
33 N oT AA GG
34 N oT AA
35 N oT TT
36 N oT TT TT CT CC
39 N oT TT CT CC AT
40 N oT AT GT CT CT
42 N oT AA GG TT TT AT
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43 N oT TT GT TT
45 N oT TT CT CC AT
46 N oT
47 N oT AA
48 N oT TT TT TT
49 N oT AT GT CT CT AT
50 N oT AT GT CT CT AT
51 N oT AT GT TT TT AA
52 N oT AT GT CT CT AT
53 N oT TT TT CT CC AT
54 N oT AA CT AT
55 N oT AT GT TT
56 N oT AA TT AA
57 N oT AT
58 N oT AT GT CT CT AT
59 N oT AA GG TT TT AA
60 N oT TT TT CC CC AT
61 N oT TT CC AT
62 N oT TT
63 N oT TT TT CT CC AT
64 N oT AT GT TT CT AT
65 N oT AT GT TT CT AT
66 N oT TT TT CT CC AT
67 NoT AT GT CT CT AT
68 N oT AA GG TT TT AA
69 N oT TT TT CT CC AT
70 NoT AT GT CT AT
71 N oT AT GT TT CT AT
72 N oT AT GT
73 N oT TT TT
74 N oT TT TT
75 N oT TT TT
76 N oT AT GT TT
78
77 N oT AA GG TT CT AT
78 N oT AT GT CT CC AT
79 N oT TT TT CT CT AT
80 N oT AT GT CT CT
81 N oT TT TT CT CC AT
82 N oT AT GT CT CT AT
83 NoT AT GT CT CT AT
84 NoT AT GT TT CT AT
85 AT
86 NoT TT AA
89 N oT TT TT CT CC AT
90 N oT AT GT CT CT AT
91 N oT TT TT CT CC AT
92 N oT AT GT CT CT AT
93 N oT AT GT TT CT AT
102 N oT AT GT CT CT AT
103
104 N oT TT TT AT
105 AA GG TT AA
106 N oT
107 N oT GG TT AA
108
109 N oT TT
114 N oT AA GG TT AA
115 N oT AA GG CT CT AT
116 N oT AA GG
117 N oT AT GT TT CT AT
118 TT
119 NoT GG TT CC
120 NoT AA TT TT AA
123 N oT AT GT CT CT AT
124 NoT AT GT CT CT AT
125 NoT AT GT TT AA
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127 N oT GG TT TT AA
128 N oT AA GG CT CT AT
129 N oT TT GT CT CC AT
131 N oT GT CT CT
132 N oT TT TT CT CC AT
135 N oT AT GG CT AA
136 AT
137 N oT AT GT CT AA
138 AT GT TT
Patients with persistent organ dysfunction aie printed in bold type (severe) 
Two patients were excluded from analysis (103 & 108) as no successful results 
were obtained.
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Table 2.8:Interleukin-8 polymorphism frequencies in patients
SNP Genotype No OD OD Total patients P value Mortality
-1722 Delete T 80 16 96 12
Inseif T 0 0 0 0.1 NS
-251 AA 19 2 21 1
AT 31 8 39 6
TT 23 4 27 0.3 4
AA+AT/TT 50/23 10/4 60/27 0.8 0.5
+396 GG 11 4 15 3
GT 27 8 35 7
TT 17 2 19 0.6 3
GG+GT/TT 38/17 12/2 50/19 0.2 0.9
+781 CC 1 0 1 0
CT 30 8 38 8
TT 21 6 27 0.8 2
CC+CT/TT 31/21 8/6 39/27 0.9 0.3
+1633 CC 14 5 19 4
CT 26 7 33 6
TT 11 3 14 0.2 2
CT+TT/CC 37/14 10/5 47/19 0.65 0.9
+2767 AA 11 6 17 4
AT 41 7 48 6
TT 5 0 5 0.2 0
AT+AA/TT 52/5 13/0 65/5 0.2 0.3
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Table 2.9: Interleukm-8 SNP genotypes in controls
Controls 1722 251 396 781 1633 2767
1 N O T AA GG CC TT
2 NOT AT GT CT CT AT
3 N O T AT GT CT CT AT
4 NOT TT GT CT CC AT
5 N O T AA GG CT TT AA
6 NOT AT GT CT CC TT
7 NOT TT GT CC CT AT
8 NOT AT GT CT CT AT
9 NOT AT GT CT CT TT
10 NOT AT GT CT CT TT
11 NOT AA GG CT TT AT
12 N O T GT CC CT AT
13 N O T AT GT CT CT AT
14 NOT AT GT CC TT
15 N O T TT GT CC CT TT
16
17 AA GT
18 NOT AA GT CC CT TT
19 NOT TT TT CC TT
20 NOT TT TT CT CC AT
21 NOT AT GT CC CT AT
22 N O T AA GT CT AT
23 NOT AA GG CT TT
24 NOT AT GT CT TT
25 N O T TT GT CC CT TT
26 NOT AA GT CT CT AT
27 NOT TT TT CT CC TT
28 NOT TT CT CC TT
29 N O T TT GT CT CC TT
30 N O T AA GG CC TT AT
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31 NOT AA GT CT CT TT
32 N OT AA GG CT CT AA
33 CC TT
34 NOT AT GT CT CT TT
35 NOT AA GT CT CC AA
36 N OT AA GG CC CC TT
37 N O T TT TT CC CC TT
38 TT
39 NOT TT TT CC CT AT
40 N O T AT GT CC CT TT
41 NOT AA GG TT TT AA
42 NOT AT GT CT TT
43 NOT TT GT CT CC TT
44 N O T AT GT CT CT TT
45 NOT AT GT CC CT AT
46 NOT AT GT CT CT AT
47 N O T GG CC CT TT
48 NOT AA GT CT TT
49 NOT AA GT TT
50 AA GT TT
51 N O T TT GT CC CC TT
52 NOT TT TT CT CC TT
53 N O T AT GT CT CT TT
54 N O T AT TT CC CT AT
55 N O T GT CC TT
56 NOT TT GG CT CC TT
57 NOT AA GG TT TT AA
58 NOT AA GT TT TT AA
59 NOT TT GG CT CC AT
60 NO T AT GG CT CT AT
61 NOT AT GT CT CT AT
62 NOT TT TT CT CC AT
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63 N O T AT GT CT CT AT
64 N O T AT GT CT CT TT
65 N O T TT TT CC CC AT
66 N O T AA GG TT TT AA
67 N O T AA GG CT CT AT
68 N O T AT GT CT CT AT
69 N O T TT TT TT CC AT
70 N O T AA GG TT TT TT
71 NO T AT GT CC CT AT
72 N O T TT TT CC CC TT
73 NO T AT GT CC CT TT
74 NO T AT GT CT CT TT
75 N O T AT GT CC CC AT
76 N O T TT TT CC CC AT
77 NOT AT GT CT CT TT
78 N O T AT GT CC CT TT
79 NOT AT GT CT CT TT
80 N O T AA GG TT CC AA
81 N O T TT TT CT CT TT
82 N O T TT TT CT CT TT
83 N O T AT GT CC CC AT
84 N O T AT GT CT CT AT
85 N O T TT TT CT CC AT
86 N O T TT TT CT CC TT
87 N O T AT TT CT CC TT
88 N O T TT GG CT CT AT
89 N O T TT TT CT CC TT
90 N O T TT CT CC AT
91 N O T AT CT CC AT
92 NOT TT CT CT TT
93 N O T TT CC CC AT
94 N O T TT CC CC TT
84
95 NOT AT CT CT TT
96 NOT TT TT CT CC AT
97 NOT AT GT CC CT TT
98 NOT TT TT CC CC TT
99 NOT AT TT TT AA
100 NOT TT CC CC
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Table 2.10 Interleukin-8 polymorphism frequencies; patients & controls
SNP Genotype Controls Patients Total number P value
-1722 Delete T 95 96 191
Insert T 0 0 0 0.1
-251 AA 23 21 42
AT 37 39 74
TT 33 27 59 0.3
AA+AT/TT 60/33 60/27 120/60 0.5
+396 GG 18 15 31
GT 50 35 87
TT 21 19 40 0.78
GG+GT/TT 68/21 50/19 118/40 0.57
+781 CC 31 1 31
CT 51 38 85
TT 8 27 35 0.8
CT+TT/CC 59/31 65/1 124/32 <0.0001
+1633 CC 35 19 53
CT 46 33 77
TT 15 14 27 0.2
CT+TT/CC 61/35 47/19 108/54 0.3
+2767 AA 9 17 25
AT 37 48 82
TT 45 5 50 0.2
AA+AT/TT 46/45 65/5 107/50 <0.0001
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Severity of acute pancreatitis
The six SNP’s (-1722, -251, +396, +781, +1633, +2767) did not exhibit differences 
in allelic frequency when compaiing mild with severe patients. The -1722 
polymorphism (deleteT/insert T) exhibited “delete T” in all patients.
No differences in allelic frequency were noted in survivors and non-survivors. 
There were 15 deaths in all but not all of these had complete results for each 
polymorphism.
Susceptibility to Acute Pancreatitis.
No differences were noted in allelic frequencies in any of the six SNPs studied in 
the IL-8 promoter region locus. When comparing genotypic dominant groups, 2 
alleles at the +781C and +2767T loci were more frequent in controls (p<0.001). 
Significant results such as these can be seen when multiple statistical analyses are 
used but in isolation are not indicative of any association between the 
polymorphism and the disease.
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2.6 Discussion
Interleukin-8 polymorphisms have been found to correlate significantly with 
clinical severity in diseases such as RSV bronchiolitis (125).
Interleukin-8 is a cytokine that is now known to be involved in the pathogenesis of 
acute pancreatitis but little is known about the genetic influences on Interleukin-8 
production. This work attempted to characterise the allelic frequencies of six 
interleukin-8 single-nucleotide polymorphisms in a population of patients with 
severe and mild acute pancreatitis to explore the relationship between the genetic 
control of Interleukin-8 production and disease severity. No significant difference 
in allelic frequencies were noted between mild and severe patients or between 
patients and controls. This indicates that there is unlikely to be an association 
between these interleukin-8 polymorphisms and acute pancreatitis. Although a 
significant difference was noted on dominant genotype grouping, this analysis is 
performed to increase statistical power and in isolation is of no clinical relevance.
It may be that there is no relationship between these six IL-8 polymorphisms and 
disease severity in pancreatitis, despite an association noted between the IL-8 
microsatellite and organ dysfunction previously. It could be argued that the sample 
size that was used was small and perhaps more results could have been obtained if a 
larger group was studied. It should however be noted that not all patients with acute 
pancreatitis as the diagnosis on admission were eligible for recruitment into the 
study, only those with an APACHE II score of 6 or greater were approached. It is 
also important to remember that DNA quality diminishes with time and that was 
also a factor m determining the length of the recruitment period, which in this case 
was approximately 2 years.
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However the complete absence of a trend in any of the six polymorphisms suggests 
that this sample was adequate at excluding a significant relationship. Another 
possibility is that other, as yet unidentified polymorphisms are responsible for 
differences in IL-8 gene expression and production. Until these are discovered, the 
role of IL-8 and other cytokines in the development of acute pancreatitis will not be 
fully understood.
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Chapter 3
Factors influencing mortality in pancreatic necrosis
3.1 Introduction
3.1.1 Severe Acute Pancreatitis
Severe Acute Pancreatitis has been previously been defined as “associated with 
organ failuie and/ or local complications such as necrosis, abscess or pseudocyst 
(144). It has been shown that various subgroups of patients exist within the 
umbrella heading of Severe Acute Pancreatitis and that outcomes for these 
subgroups can vary significantly. The qualitative difference between the presence 
of MODS and the characteristics of MODS (early resolving v 
persistent/deteriorating) with respect to mortality has aheady been discussed (23). 
Similai'ly, patients who develop local complications are not all alike with respect to 
morbidity and mortality. The mortality rate is up to twice as much for infected 
pancreatic necrosis compared with pancreatic abscess and three times as much 
compared with pseudocyst formation (145,146). The main determinant of mortality 
in patients with severe AP as defined above is the degree of organ dysfunction (66).
3.1.2 Management of MODS in Severe Acute Pancreatitis
Recent UK guidelines on the management of patients with severe AP suggest that 
the patient should be closely monitored, with maximal supportive therapy, 
including intravenous (IV) fluids, supplementaiy inspired oxygen and analgesia (7). 
The vast majority of patients with MODS have respirator}^ failure either alone or in 
combination with other organ failuie. In one study, 90% of patients with AP who 
died from MODS did so as a result of respiratory failuie (65). Consequently, most 
AP patients with MODS require ventilation and are managed in an intensive care
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setting where renal replacement therapy and inotropic support can also be given if 
required (147).
3.1.3 Sepsis and Severe Acute Pancreatitis
The development of MODS in tlie early course of AP has already been discussed. 
Those who develop MODS in the second and third weeks do so predommately in 
association with infected pancreatic necrosis. (49,148) Infection of pancreatic 
necrosis tends to develop 2-3 weeks after symptoms start in approximately 40-70% 
of patients who develop necrosis(149). The risk of infection increases with the 
extent of necrosis. The involved organisms tend to be mostly gram-negative with 
an enteric origin (149,150) suggesting the gastro-intestinal tract as the source of 
infection. This is the basis of the hypothesis of failure of gut function as a barrier to 
infection(30). It has been shown that intestinal permeability is increased in patients 
with severe AP (151) and this, amongst other factors, can allow bacterial 
translocation (152). Other possible routes of infection have been suggested 
including haematogenous, lymphatic or via the pancreatic and common bile duct 
(30). Enteral nutrition has been shown to reduce bacterial translocation to 
mesenteric lymph nodes in an animal model of AP. Clinically enteral feeding has 
beneficial effects in patients with AP by reducing septic complications when 
compared with total parenteral nutrition (37).
3.1.4 Development of Pancreatic Necrosis
Pancreatic necrosis was defined at the 1992 Atlanta Consensus Conference as 
“diffuse or focal area(s) of non-viable pancreatic parenchyma wliich is typically 
associated with peri-pancreatic fat necrosis (58). It is important to distinguish this
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from pancreatic abscess which may have some necrotic tissue within it (Figure 3.1). 
Previously, ambiguous terminology relating to inflammatoiy complications of AP 
has been used interchangeably, making it difficult to compare different reports in 
the literature.
A pancreatic abscess is a circumscribed intra-abdominal collection of pus, usually 
in proxhnity to the pancreas, containing little or no pancreatic necrosis, which 
arises as a consequence of acute pancreatitis.
Figure 3.1: Atlanta Definition of Pancreatic Abscess (58)
Pancreatic abscess is associated with a much lower mortality rate than pancreatic 
necrosis (153) and tends to occur at a later point in the disease (146). Of those who 
develop necrosis, up to 70% are likely to become infected. The risk of infection 
increases with the extent of necrosis and duration of the disease (149). The 
management of sterile pancreatic necrosis has been controversial. Previously, 
patients with sterile necrosis were considered to be at risk of subsequent infection 
and of organ failure, therefore, surgical debridement was performed with the 
rational that by removing necrotic tissue, these risks are reduced. However, this 
approach can introduce infection into previously sterile necrosis and this has 
accoimted for up to 30% of the total number of patients with IPN in the past. Over 
the last five to ten yeai's, consensus opinion has shifted. More stringent indications 
for sui'gery in patients with sterile necrosis to include only those with severe AP 
unresponsive to maximal supportive therapy were suggested (154). However, the 
most recent guidelines suggest that surgical intervention should be reserved for 
patents with infected necrosis (7,39).
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3.1.5 Diagnosis of Infected Pancreatic Necrosis
A high clinical suspicion of pancreatic necrosis is necessary to allow early 
diagnosis. Delayed diagnosis is associated with a worse outcome(155). Clinically, 
patients complain of worsening abdominal or back pain, and may develop signs of 
SIRS and/ or MODS as well as an elevated CRP. They may have an abdominal 
mass on examhiation. The best imaging teclmique for identifying pancreatic 
necrosis is CT scanning, with intravenous contrast enhancement (27). This can 
reveal the extent and site of necrosis as well as indicating extra-pancreatic disease. 
This modality however, cannot always identify infection, thougli air indicative of 
gas-forming organisms can be seen in 20-55% of patients with necrosis (47,51). 
Differentiation between sterile and infected pancreatic necrosis is crucial in 
planning further management. This can be achieved with Fine Needle Aspiration 
(FNA) and culture or gram staining of necrotic material. Radiologically (US or CT) 
guided FNA has been found to be a safe and reliable procedure with high rates 
(above 95%) of sensitivity and specificity in the diagnosis of IPN (156,157). 
Although this procedure has low complication rates, it should only be performed in 
patients with CT evidence of necrosis as well as systemic signs of sepsis (39) as the 
risk of introducing hifection to sterile necrosis is not insignificant (150,157).
3.1.6 Mortality rates in patients with Infected Pancreatic Necrosis
Infected Pancreatic necrosis (IPN) has been recognised as one of the important 
clinical factors affecting both organ failure and mortality in acute pancreatitis. As 
discussed previously, it is known that the majority of patients who develop MODS 
after the first 2 weeks from the onset of symptoms do so in association with IPN. It 
was recognised over 15 years ago that patients who developed pancreatic necrosis
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were more likely to die and have organ failure (158). The presence of necrosis in 
itself is a risk factor for MODS but this is less associated with mortality than the 
presence of MODS (150,159). It is now generally accepted that patients with 
infected rather than sterile pancreatic necrosis tend to have a worse outcome as they 
are more likely to have sepsis-related MODS (46). The mortality rate in patients 
who develop infected pancreatic necrosis varies widely between centres and studies 
(Table 3,1), This can range from 10% to as high as over 70%. Even in a relatively 
small area such as the UK, the mortality can vary from 14% in Southampton to '1:'
69% in Leeds, with Glasgow having a mortality rate of 28%.
i;
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Table 3.1 Mortality Rates in patients with PN
Study Year Patients
11
Mortality
(%)
Procedure
Allardyce(49) 1987 17 82 Open necrosectomy
Wilson (158) 1988 21 38 *Open necrosectomy/ 
pancreatic resection
Bassi (146) 1990 55 24 * Open necrosectomy & 
Lavage
Bradley(144) 1994 71 15 Open &- packing then open 
& post-op lavage
R an(160) 1997 52 15 Open necrosectomy & 
Lavage
Farkas (161) 1996 142 6 Open necrosectomy & 
Lavage
Fernnadez-del 
Castillo (162)
1998 36 6 Open necrosectomy & 
Lavage
Freeny(163 1998 34 12 Percutaneous 
Catheter drainage
Buchler(28) 2000 29 24 Open necrosectomy & 
Lavage
Ashley (164) 2001 34 12 Necrosectomy / 
percutaneous drainage
Hungness (165) 2002 18 23 Open necrosectomy
Malangoni (66) 2004 13 15 Open necrosectomy & 
Lavage
Connor (166) 2005 88 28 * Minimally invasive & open 
pancreatic necrosectomy
Buchler (56) 2002 92 19 Open necrosectomy and 
lavage
* Includes patients without infected necrosis
It has been demonstrated that less aggressive techniques are associated with 
improved mortality rates. Previously, total pancreatectomy has been performed in 
cases of IPN with high mortality rates. The introduction by Beger of a post­
operative closed lavage system hi 1991 has contributed to reduced mortality 
rates(167).
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3.1.7 Factors affecting mortality in IPN
Several risk factors have been found to affect mortality in patients with infected 
pancreatic necrosis (Table 3.2) and it likely that these factors operate to different 
extents in diverse patient populations.
Table 3.2 Factors affecting Mortality in patients with IPN
Risk Factor Evidence Potential Intervention
Presence of (66,168) Limiting MODS by minimising
MODS “surgical hit”
Extent of 
Necrosis
(149,169 Limiting necrosis by debridement
Type of (28,170) Avoidance of prophylactic
Infection antibiotics
Treatment of Resistant organisms
Surgical (169,171) Minimally invasive
Intervention Definitive debridement
Timing of (162,165) Delay until demarcation occuis
Surgery 2 weeks after onset of AP.
No benefit in delay beyond 4‘’^ 
week
Presence of MODS in patients with IPN
The presence of MODS in patients with an established diagnosis of IPN is 
associated with a negative outcome. Untreated, (i.e., no surgical intervention) the 
mortality rate may be as liigh as 100% hi patients with MODS and IPN (172). 
Type of Infection & Prophylactic Antibiotics
Recently, there have been increasing numbers of gram-positive organisms 
colonising necrotic pancreatic tissue. This is thought to be due to the widespread
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use of prophylactic antibiotics. Randomised studies have shown conflicting 
evidence regarding prophylactic antibiotic usage and mortality (173,174). However, 
the incidence of antibiotic-resistant organisms has increased in recent years and is 
associated with higher mortality rates (175). Conti oversy remains on whether to use 
prophylactic antibiotics. This will be discussed further in the next chapter.
Referral patterns
It should be noted that due to various local and geographical factors, tertiary 
referral centres have wide variations in the referral practices of the sur rounding 
district hospitals. This can also impact on outcome as it has been shown that late 
referral to a specialist unit is associated with a higher overall mortality (176).
3.1.8 Surgical Procedures for pancreatic necrosis 
Laparotomy and Debridement
In 1984 Knol and his colleagues remarked that ideal surgical treatment for 
necrotizing pancreatitis remains a matter o f debate ” in their paper describing an 
open technique of pancreatic debridement in addition to “marsupialisation” (open 
packing) of the lesser sac, with repeated laparotomy at intervals of 2-5 days for 
further packing (177). Until then, the mainstay of surgical therapy for necrotizing 
pancreatitis had been laparotomy with debridement of devitalised pancreatic tissue 
and simple closed drainage of the pancreatic bed (158,178) though in some cases, 
partial or total pancreatic resection was performed which, in retrospect may have 
been a somewhat aggressive approach for patients without total pancreatic necrosis. 
Over twenty years later, the appropriate surgical management for necrotising 
pancreatitis remains a matter of debate but there have been several evolutions of
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surgical treatment during this time. The technique of laparotomy, retroperitoneal 
exploration and simple drainage was widely adopted duiing the mid 1980’s with 
slight variations but generally involving repeated second-look laparotomies and 
debridement of further necrosis with or without packing of the lesser sac. A new 
technique of open packing was developed (53) where the abdominal wound was not 
closed primarily and packs were left in the lesser sac. The wounds were allowed to 
heal by secondary intention. This was later modified by delayed closur e of the 
wound whilst continuing with post-operative lavage(53). Continuous post-operative 
local lavage was widely adopted as an adjunct to initial open debridement allowing 
the removal of further debris and infected material via drainage tubes placed into 
the pancreatic bed and lesser sac during the initial (146,148). This removed the 
need for mandatory further laparotomy procedures in patients who were already 
critically ill and the associated increased risk of frirther morbidity and increased 
mortality. In a small prospective study of 24 patients, Nordback compared patients 
with necrosis post laparotomy with lesser sac lavage or simple drainage, no 
difference in outcome was noted. Septic complications were not improved with 
lavage (179).
The change to lapaiotomy plus continuous post-operative lavage rather than 
drainage was associated with a reduction in mortality rate and was adopted by 
many centres though no randomised trials have been perfoimed looking at 
laparotomy with packing versus lavage. Several centres continued with open 
necrosectomy and closed packing with low mortality rates hi patients with infected 
and sterile pancreatic necrosis (162). Overall, closed post-operative lavage is 
associated with lower mortality rates, fewer gastro-intestinal fistulae and bleeding 
complications when compared with open packing (180). The lavage is continued
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for approximately 3-4 weeks until sepsis resolves. Open packing remains an option 
in patients with coagulopathy or difficult intra-operative bleeding.
Percutaneous & Endoscopic procedures
During the last decade, there has been a move towar ds developing less invasive 
procedures for managing pancreatic necrosis. Drainage of pancreatic 
abscess was described in 1981 using a percutaneous route (181) but this procedure 
was not suggested for pancreatic necrosis until more recently where it serves a 
useful role in temporising the situation until definitive surgery can be performed. 
The theoretical advantage of minimally invasive procédur es, is a reduction in the 
inflammatory response associated with the trauma of surgery. It has been shown in 
several other conditions that laparoscopic procedures initiate a reduced systemic 
response compared to the equivalent open operation, even in elective patients (182). 
Baron in 1996 described a teclinique of endoscopic cyst-gastrostomy in 
combination with naso-cyst lavage to remove further debris with good results (183). 
However, this procedure was used in patients with pancreatic pseudocysts or 
abscesses and only 28% were infected at the time of intervention. Secondary 
infection however occurred m 38% of these patients, who required further 
intervention. They have since suggested that collections with solid debris of more 
than 1cm in size are not suitable for this technique(184). Following on from this, 
Freeny and colleagues, in 1998, described a series of patients with infected 
pancreatic necrosis who were primarily managed with percutaneous drainage using 
multiple catheters and lavage(163). This was achieved successfully with resolution 
of sepsis in 47% of patients. However the remaining 53% of patients required 
surgical intervention at some stage (26% as emergency procedures). The mortality
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pancreatic necrosis who were primarily managed with percutaneous drainage using 
multiple catheters and lavage(163). This was achieved successfully with resolution 
of sepsis in 47% of patients. However the remaining 53% of patients required 
surgical mtervention at some stage (26% as emergency procedures). The mortality 
rates in both of these studies are low but both studies were carried out in highly 
selected patients, usually witli no significant organ dysfunction.
Further small series of patients undergoing minimally invasive procedures for IPN 
are described with reasonably good results in selected patients(185).
3.1.9 Pilot Study
In 2000, the Glasgow group described a percutaneous necrosectomy technique 
aimed at surgical debridement as well as simple drainage of necrotic abscess 
cavities (171). This method involves initial percutaneous, CT guided drainage of 
the area of necrosis and placement of a drain. The patient is then taken directly to 
theatre where the drain is changed over a guide-wire after administration of general 
anaesthesia. The area of necrosis is then visualised directly by using a modified 
rigid nepliroscope after dilatation of the tract using a balloon dilator, allowing 
insertion of a 34French gauge Amplatz sheath. Lavage is performed until the return 
fluid is clear. The necrotic tissue is debrided piecemeal with continuous lavage. 
Retrieved material is sent for bacteriological culture. A drain (28F) is passed into 
the length of the cavity facilitating post-operative lavage.
This procedure can be repeated weekly until the devitalised pancreas is debrided 
adequately and sepsis settles. The patient is not subjected to open laparotomy 
routinely, hidications for proceeding to open laparotomy include haemorrhage, 
perforation of colon/ small bowel, mesenteric ischaemia and extensive peri-
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pancreatic necrosis extending outwith the retroperitoneum mto the pai'acolic and 
peri-nepliiic spaces.
3.2 Hypothesis and Aims 
Hypothesis
Minimally invasive surgical debridement of infected pancreatic necrosis may 
reduce the incidence of MODS and the need for postoperative ICU thereby 
reducing mortality.
Aims
1) To compare and describe outcomes for patients undergoing percutaneous and 
open necrosectomy for infected pancreatic necrosis admitted to Glasgow Royal 
Infiimary over a 13 year period.
2) To examine other factors that may affect outcome in this population
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3.3 Patients and Methods 
Study Design.
This review was carried out retrospectively on patients admitted between Dec 1989 
and March 2003 who underwent pancreatic necrosectomy for infected pancreatic 
necrosis. The data points collected for each patient are outlined below (Table 3.3).
Data collected
Gender
Age
Aetiology
Referring Hospital
Date of admission to hospital
Date of admission or transfer to GRI
Length of hospital stay
Index pancreatic necrosectomy procedm e
Subsequent operative procedures
Surgical complications
Other invasive procedures
Intensive Care Unit stay
High Dependency Unit stay
Post-operative Complications
Outcome
Microbiology of pancreatic necrosis 
Use of nronhvlactic antibiotics
Table 3.3 Data points for pancreatic necrosectomy patients
Patients were defined for the purposes of this study as having either open (OPEN) 
or percutaneous necrosectomy (PPN) depending on the index pancreatic 
necrosectomy procedure. In the event of conversion from percutaneous to open, the 
patients were allocated to the PPN group based on intention to treat.
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Necrosectomy Procedures
Those in the OPEN gi'oup had an initial laparotomy and debridement of pancreatic 
necrosis. This was followed by either continuous postoperative lavage or open 
packing.
Patients in the PPN group underwent a percutaneous pancreatic necrosectomy as an 
index procedure. Any further percutaneous procedures were also recorded includmg 
sinus tract endoscopy.
MODS and ICU
Patients vary in their requirements for Intensive care (ICU). Physiological 
parameters were not available for all patients, precluding assessment of severity of 
MODS using a MODS scoring system. Admission to ICU in GRI is restricted to 
patients with respiratory failure requiring ventilatory support, with or without 
additional organ mvolvement. ICU admission was therefore used as a marker of 
significant MODS.
Microbiology
Microbiology sampling included CT-guided FNA of areas of pancreatic necrosis 
pre-operatively, pancreatic tissue or fluid taken during the index necrosectomy 
procedure. Data on antibiotic and anti-fungal usage was taken directly from 
patient’s case-notes where available. Additional information was obtained from 
archived microbiology records.
Setting
The study took place in the Lister Department of Surgery at Glasgow Royal 
Infirmary in Glasgow. Patients studied were admitted to the general surgical wards,
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the High Dependency Unit (HDU) or the Intensive Care Unit (ICU) within 
Glasgow Royal Infirmary depending on their clinical status. In some circumstances, 
due to limited bed availability in ICU, patients were transferred to other Intensive 
care units within the city.
Inclusion and Exclusion Criteria
All patients witli pancreatic necrosis requiring necrosectomy were identified and 
their details recorded prospectively. Those with infected pancreatic tissue at the 
index necrosectomy procedure were included. Those with sterile necrosis were 
excluded for the purposes of this study.
Data Collection
Case records were requested for all patients included in the study. The medical 
records department assisted by permitting access to case notes.
Information from the case notes was recorded on a specifically designed database 
using Microsoft Excel. The database included a section for recording a range of 
clinical, biochemical and haematological parameters and calculating APACHE II 
and SIRS scores.
Additional information was obtained from other sources including microbiology 
results with the assistance of Dr Hood (Microbiology Lab). Microbiology results 
for patients admitted prior to March 1998 were stored in computerised files in the 
Information Technology department whose staff kindly assisted with accessing 
some of these results.
Additional information regarding ICU stay was obtained from the ICU secretary 
(Sheila Stewart).
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Statistical Analysis
A computerised statistical programme (SPSS 9) was used to analyse the data. 
Mann-Wliitney-U testing was used on non-parametric data. Two-sided Chi-square 
analysis was used on parametric values. Dr Wilson Angerson was consulted for 
advice on statistical methods.
A p value <0.05 was considered significant.
Ethical Approval
This study was a retrospective audit of patients undergoing two differing 
approaches to pancreatic necrosectomy. All patient details were anonymised. 
Formal ethics approval was not required.
3.4 Pancreatic Necrosectomy Results
Between December 1989 and March 2003,107 patients underwent pancreatic 
necrosectomy. Of these, 8 patients did not have evidence of infected necrotic tissue 
at the time of the initial procedure and were excluded from subsequent analysis. 
Patients studied had either open (OPEN) or percutaneous (PPN) pancreatic 
necrosectomy. Two patients were converted from percutaneous necrosectomy to 
open laparotomy and necrosectomy, during the index procedure for one patient and 
for a second, duiing their second percutaneous procedure. Botli have been analysed 
within the PPN group based on pre-operative intention to treat. In total 46 patients 
in the PPN group and 53 in the OP group were included.
105
Patient Characteristics
The median age of all patients was 54 years (range 18-88 years) and did not differ 
significantly between both groups. The gender distribution was also similar (Table
3.4).
Patients managed in this specialist unit were frequently admitted initially to other 
hospitals in the West of Scotland or further and transferred to Glasgow Royal 
Infirmary (GRI) either after clinical deterioration or after a diagnosis of infected 
pancreatic necrosis was made.
Table 3.4: Patient Characteristics
(OP) (PPN) Total P value
Number of patients 53 46 99
Median Age (years) 53 (39-67) 55 (39-71) 54 (39-69) 0,45
Sex Ratio (M:F) 36:17 33:13 70:30 0.72
Admitted to GRI 16 15 31
Transferred from elsewhere 37 31 68 0.75
Sixty-nine percent of patients in this study were initially admitted to another 
hospital before transfer to GRI for definitive treatment. The median time to transfer 
was 16 days in all referred patients. The distribution of referred patients between 
both groups is similar.
Aetiology
The commonest cause was gallstones followed by alcohol. Iatrogenic and 
idiopathic causes were less common. There were 5 patients with AP secondary to 
ERCP in the open group with none having this aetiology in the PPN gi'oup, the only 
significant difference in the distribution of aetiology between the two groups (Table
3.5), Data regarding aetiology was unavailable for 4 patients.
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Table 3.5 Aetiology of acute pancreatitis in patients with IPN
(OP) (PPN) Total
Gallstones 33 30 63
Alcohol 10 9 19
Iatrogenic 5 0 5
Idiopathic/ unknown/ otlier 5 7 12
Procedures
Fifty-three patients underwent an initial open pancreatic necrosectomy. 46 patients 
had a percutaneous procedui e (PPN). One of these patients was converted to an 
open laparotomy due to extensive retroperitoneal necrosis and mesenteric vessel 
bleeding. (This patient also required a splenectomy)
The number of patients requiring pancreatic necrosectomy increased over the study 
period and reached a peak of 19-patients/ year in 2001 (Figure 3.4). The overall 
mean is 8-patients/ year over the total study period.
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Figure 3.2: Procedures Dec 1989- March 2003 
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Note: One patient in Dec 1989 and a patient in early 2003 were included with 
adjacent years.
Additional Procedures
In 38 patients, 30 in the OPEN and 8 in the PPN group, a single procedure was 
required. Thirty-eight PPN patients required further percutaneous debridement 
procedures and these were performed over the subsequent weeks (Figure 3.4). A 
median number of 3 PPN procedures were performed for each patient.
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Figure 3.3: Number of Percutaneous (PPN) procedures
In addition to pancreatic necrosectomy and debridement at the index procedure, a 
number of other procedures were also performed.
In the OPEN group, several additional pancreatic resection or bypass procedures 
were performed including gastro-pancreatostomy, cholecystoduodenostomy, 
panctreatico-jejeunostomy roux-en-y and distal pancreatectomy. Four patients had a 
cystgastrostomy.
A proportion of patients had colonic complications associated with pancreatic 
necrosis. Nine patients in the OPEN group required colonic resection compared 
with 3 in the PPN group. (p=0.1)
Of these, 8 patients in the OPEN group had colonic resection at the same time as 
the initial necrosectomy. Seven of the OPEN patients had a right (3) or extended
109
right (4) hemicolectomy for poor colonic perflision or necrosis of the colon. The 
remaining 2 OPEN patients had a transverse colectomy and a left hemicolectomy 
for extensive peripancreatic necrosis.
In the PPN group, one patient was converted to open during the 2"  ^PPN for 
perforated transverse colon requiring a right hemicolectomy. Two otlier PPN 
patients required laparotomy following their 3*^  procedure for colonic ischaemia 
associated with extensive peri-pancreatic necrosis.
Further open procedures for persisting necrosis/ inflammation were performed in 8 
patients in the open group, 2 with colonic complications, 4 with persistent necrosis 
and 2 with intra-abdominal/ pancreatic abscesses requiring debridement.
Four of the PPN patients required open laparotomy after an initial percutaneous 
procedur e for ongoing necrosis/ pancreatic inflammation. Tlnee of these have been 
discussed in relation to colonic complications. The fourth patient required open 
debridement of a persisting pancreatic abscess.
Cholecystectomy
Gallstones were identified as the main aetiology of acute pancreatitis in 63 patients, 
33 in the OPEN and 30 in the PPN group. Thirty-seven patients in the OPEN group 
had a cholecystectomy performed at the index procedure.
Cholecystectomy was carried out duiing the same admission in a total of nine 
patients in the PPN group. Two underwent cholecystectomy at the index procedure; 
two patients had an open cholecystectomy during laparotomy at a later date. Five 
patients had a delayed laparoscopic cholecystectomy prior to discharge.
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Haemorrhage
Bleeding was an indication for ftnther surgery in 5 patients. In the open group, one 
patient had persistent problems, initially with a biliary leak and bleeding from the 
hepatic bed, followed by pancreatic vessel bleeding which required relaparotomy 
the following day. This was complicated by duodenal bleedmg with a further 
laparotomy 10 days later. Excision of the first and second parts of the duodenum 
and oversewing of the duodenal stump was performed. He proceeded to have 2 
embolisation procedui'cs of the hepatic arteiy over the following 3 weeks and was 
eventually discharged 3 months later.
Another patient in the OPEN group bled from a superior Mesenteric artery 
pseudoaneurysm, this required laparotomy and oversewing after 2 unsuccessful 
embolisation attempts.
Tliree patients in the PPN group required laparotomy for bleeding complications. 
One of these patients also had persisting pancreatic and duodenal necrosis resulting 
in gastroduodenal arterial bleeding. This patient died intra-operatively.
One patient has already been mentioned above who required laparotomy for 
persisting pancreatic necrosis involving colon. Post-operatively, significant 
bleeding was noted and due to clinical deterioration, underwent re-laparotomy in 
ITU and subsequently died. The third patient had bleeding hi association with 
colonic infarction necessitating laparotomy.
Five patients in the open group required further lapaiotomy after initial pancreatic 
necrosectomy for removal of packs. One patient required splenectomy, and another 
patient had ligation of the splenic artery perfoimed.
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Effect of Type of Procedure on Outcome in Patients with Infected Pancreatic 
Necrosis 
Multiple Organ Dysfunction and ICU Admission
Patients in both groups had MODS to a variable extent and differed in their 
requirements for Intensive cai'e (Table 3.6). More patients in the OPEN group than 
in the PPN group required ICU admission at some point during their total hospital 
stay (45/53 v 26/46 p=0.002).
OPEN PPN p~value
No ICU admission 8 20 0.002
Pre-op ICU admission 15 18 0.2
Post-op ICU admission only 30 8 0.003
Total patients in ICU 45 26 0.002
Total 53 46
Table 3.6 :ICU Admission 
Pre-operative ICU admission
Pre-operative ICU admission was fuifher subdivided into two groups as follows. 
Those with transient MODS requiring ICU care in the early phase of the illness 
(within two weeks of admission), which improved sufficiently to be discharged 
from ICU care before surgical intervention for necrosis. The other group consisted 
of patients who developed MODS pre-operatively but who had persistent MODS 
requiring ICU care up to and including the time of their index necrosectomy 
procedure (Table 3.7)
The time from initial hospital admission to ICU admission was similar in both 
groups regardless of the dynamics of MODS. Total ICU stay for all patients and 
survivors was significantly longer for PPN patients in the transient MODS group 
but not in those with persistent MODS. Mortality rates, though liigher m those with 
persistent MODS compared with transient MODS, were similar when comparing 
both the OPEN and PPN groups.
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Pre-
Operative
ICU
OPEN PPN Total P
value
Transient Number of 7 6 13
MODS patients
Time to ICU from 2 (1-7) 2.5 (1-7) 2 (-7) 0.384
hospital +/- 2.5 +/- 2.3 +/- 2.4
admission (days)
Total ICU Stay 8 11.5 8 0.036
(median days) +/- 5.8 +1-92 +/- 8.4
Mortality 2/7 1/6 3/13 0.612
(28.5%) (16.7%) (23%)
Total ICU stay in 2 (1-8) 11 (8-33) 8 (1-33) 0.015
survivors +/- 3.8 +/-10.3 +/- 9.2
Persistent Number of 8 12 20
Peri-operative patients
MODS
Time to ICU from 5 (1-19) 4 (2-47) 4(1-47) 0.863
hospital +/- 6.2 +/- 12.9 +/-10.7
admission
Total ICU Stay 18.5 (5-32) 28.5 (9-182) 24 (5-182) 0.053
+/-10.1 +/- 46.9 +/- 38.4
Mortality 5/8 5/12 10/20 0.65
(62.5%) (41.6%) (50%)
Total ICU stay in 5 (5-32) 27 (19-182) 27 (5-182) 0.14
survivors +/- 15 +/-S8 +/-53
Table 3.7: Pre-operative ICU Admission 
Post-operative ICU admission
In total 64 patients required ICU cai'e post-operatively, this differed significantly 
between the two groups (42/53 v 22/46 p^O.OOl) (Table 3.8).
In patients who received pre-operative ICU care, a similar proportion in each group 
required additional post-operative ICU care (12/15 v 14/18, p=0.87).
In the OPEN group, more patients were admitted to ICU for the first time post- 
operatively. This is significantly higher than the proportion of patients in the PPN 
group (30/53 v 8/46 p=0.003).
The median time in days from hiitial admission to hospital and first admission to 
ICU was comparable for both groups. Mortality rates in patients with post-operative
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ICU admission were not significantly different between the two groups (16/42 v 
13/22, p=0.1). The median length of ICU stay in survivors ranged between 5.5 and 
25 days in the OPEN and PPN groups respectively and was significantly greater in 
PPN patients (p=0.005).
Post-Operative ICU OPEN PPN Total P value
Pre- operative ICU and Post­ 12/15 14/18 26/33 0.87
operative ICU
Post-op ICU only 30 8 38 0.003
Total Post-op ICU 42 22 64 0.001
Time to ICU from hospital 17(1-19) 8.5 (1-99) 15(1-99) 0.75
admission +/- 14 +/-30 +/“ 21
Total ICU Stay 8 (1-46) 20(1-182) 10(1-182) 0.009
+/- 11.5 +/- 38.6 25.5
Mortality 16/42 13/22 29/64 0.1
(38%) (59%) (45%)
Total ICU stay in survivors 5.5 (1-43) 25 (1-182) 8(1-182) 0.005
+/-10.7 +/- 55.6 +/- 33
Post-op stay in survivors 5.5 9.5 6 0.236
(+/-6.5) (+/-10.3) (+/-7.3)
Table 3.8: Post-Operative ICU admission 
Mortality
The overall mortality rate was almost identical in both groups (Table 3.9). Sixteen 
patients of 53 m the OPEN group died, compared with 14 of 46 patients in the PPN 
group (p=0.97). A similar proportion of patients in both groups had pre-operative 
MODS requiring ICU admission (7/16 v 6/14, p=0.96). Of the remaining 17 
patients who died, 16 required post-operative ICU admission. One patient died 
intra-operatively with no pre-operative ICU care requirements.
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OPEN PPN P value
Mortality 16/53 14/46 0.97
(30.1%) (30.4%)
Pre- Operative ICU 7 Pre-op ICU 6 Pre-op ICU 0.96
Admission 9 Post-op ICU 7 Post-op ICU
(1 no ICU*)
Hospital Stay 39.5 (18-98) 70(24-114) 0.051
+/- 23 +/-29
Table 3.9: Mortality Rates for Pancreatic Necrosectomy Procedures 
* Significant intra-operative gastroduodenal arterial haemorrhage.
Though median total hospital stay was greater in PPN patients who died, this just 
approaches significance (39.5 v 70 days, p=0.051). Hospital stay is similar in 
survivors when comparing OPEN and PPN patients (median 70 v 66 days, p=0.47) 
Distribution of mortality
The proportion of deaths each year varied and the distribution throughout the study 
period is shown in Figui'e 3.4
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Figure 3.4 Yearly Mortality rates 
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Mode of death
As reported previously, the mortality rates are similar in both groups. The mode of 
death, however, is different. The majority of patients had MODS as the main cause 
of death post-operatively (Table 3.10). However, more haemorrhagic complications 
were encountered in the PPN group (1/15 OPEN v 5/14 PPN, p=0.044) (Table 
3.11).
OPEN PPN
Mortality 16 14
MODS alone 15 9
Bleeding alone 1 1
Bleeding and MODS 0 4*
MODS & Mesenteric ischaemia 2 1
Table 3.10: Mode of Death for Pancreatic Necrosectomy Procedures
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* One patient had colonic ischaemia in addition to bleeding
Table 3.11: Bleeding Complications in PPN patients
Mesenteric venous bleeding post-operatively 
requiring lapaiotomy
Post-operative bleeding requiring laparotomy 
in ITU
Colonic ischaemia and post-op bleeding 
requiring laparotomy
Gastroduodenal Artery bleeding secondary 
to duodenal necrosis
Effect of pre-operative MODS on outcome in IPN
As noted previously, the proportion of patients with pre-operative MODS was 
similar in both the OPEN and PPN groups (15/52 v 18/46). In the total group, the 
mortality rate of those with any pre-operative MODS compared to those without 
was not significantly different (13/33 v 17/66, p=0.16) However when comparing 
those patients who had persistent pre-operative MODS to those without, the 
mortality rate was much higher (10/20 v 20/79, p=0.032)(Table 3.12). The type of 
procedure was not related to outcome in patients with persistent pre-operative 
MODS. Five patients in each of the PPN and OPEN groups had persistent pre- 
operative MODS and died. All patients with persistent pre-operative MODS 
required post-operative ICU care compared to only 57% of those without (20/20 v 
45/79, p<0.001)
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Table 3.12: Effect of persistent Pre-op MODS on outcome
Persistent
pre-op
MODS
No
persistent
MODS
p-value
Number 20 79
Mortality 10 20 0.032
Post-op ICU admission 20 44 <0.001
Percutaneous/ Open necrosectomy 12/8 34/45 NS 0.17
Mortality PPN/ OPEN 5 PPN/ 5 OP 9/11 NS 0.9
Total 53 46
Other factors affecting mortality 
Referral patterns
Thirty patients were admitted directly to the sui'gical unit at Glasgow Royal 
Infirmary at the onset of their symptoms. Sixty-nine patients were referred from 
other hospitals in the West of Scotland region upon diagnosis of pancreatic necrosis 
and/ or MODS. The mortality rate in patients referred from other hospitals 
compared to GRI-admitted patients varies with a slightly lower mortality in GRI- 
admitted patients (5/30 v 25/69, p= 0.05) (Figure3.5).
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Mortality rates In tertiary referrals
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Figure 3.5: Mortality rates in tertiary referrals
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Age related mortality
There is a significant association between older age and mortality (p<0.001) 
Table 3.13: Age and mortality
Age Group Survivors Deaths Total
15-30 9 0 9
30-45 22 3 25
45-60 19 12 31
>60 19 15 34
Totals 69 30 99
Multi variate analysis of factors affecting outcome
Several factors in this group of 99 patients with infected pancreatic necrosis have 
contributed to a fatal outcome and post-operative MODS (Table 3.14). These 
factors have been investigated in isolation in the previous section. Using multi-
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variate analysis these factors were assessed in relation to each other to avoid any 
confounding bias. Microbial factors have been included here and are discussed in 
greater detail in the next chapter (Chapter 4).
Table 3.14 : Factors affecting outcome in IPN
Factor affecting outcome Mortality 
p value
Post-operative ICU 
p value
Increasing Age 0.0003 0.7
Tertiary Referral 0.05 0.2
Pre-operative ICU stay 0.1 0.5
Persistent pre-op MODS 0.03 0.0003
Prophylactic Antibiotics 0.8 0.3
PPN necrosectomy 0.9 0.002
Fungal infection 0.003 0.3
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3.5 Discussion
Feasibility of percutaneous necrosectomy
Controversy remains regarding the optimal surgical procedure to combat infected 
pancreatic necrosis. Sepsis-related MODS pre-operatively combined with a 
significant surgical insult in the form of open pancreatic necrosectomy is associated 
with high mortality rates. Many new techniques have been explored to try and limit 
the surgical insult to these patients. Simple drainage catheters are ineffective in 
fully removing all necrotic debris from the abscess cavity and are deemed 
unsuitable for collections with solid components of > 1cm in size (184). Several 
disadvantages of percutaneous drainage techniques have previously been suggested 
including the number of extra procedures needed, and the failure to adequately 
clear the necrotic area resulting in ongoing sepsis. A high proportion of patients 
who are initially managed percutaneously eventually requhe definitive open 
debridement to deal with the solid necrotic component. In high-risk patients with 
organ dysfunction, endoscopic and percutaneous drainage can be used to temporise 
a patient’s condition until delayed necrosectomy can be performed. These have 
been described earlier in the chapter. Freeny et al reported that 47% of patients in 
his study avoided a laparotomy either for elective fistula repair or open 
necrosectomy for uncontrolled sepsis (163). The results shown above indicate that 
laparotomy was avoided in 37/46 patients (80%) in the percutaneous group, of 
winch 29 (63%) were cured. This contrasts with 27/53 (51%) patients in the open 
group who required further sui'gical intervention. Twenty-four (45%) of these 
patients required lapaiotomy. The patients in the percutaneous group had a median 
of 2 (range 1-6) percutaneous procedures performed and although the total number 
of additional procedures is greater, the percutaneous operating time is much less. In
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addition, total hospital stay, though expected to be longer in the percutaneous group 
due to the number of procedures required, was in fact similar. Post-operative stay 
was slightly longer in the percutaneous group but not significantly so.
Mortality Rates
Post-operative haemorrhage has been recognised as a major challenge in the 
sui'gical management of IPN with an incidence of approximately 26%. In this 
series, a significantly higher proportion of deaths in tlie percutaneous group were as 
a result of post-operative bleeding. It should be noted that the majority of the 
haemorrhagic complications occurred in the early stages of using the percutaneous 
teclinique. Since then, intra-operative and post-operative bleeding has been 
minimised by using a more cautious approach to debridement of devitalised 
pancreatic tissue, with improved results in those patients.
Post-operative ICU requirements
The observation fi'om the initial study in this institution (171) that the percutaneous 
technique results in less organ dysfunction post-operatively has been verified. 
Significantly less patients required ICU cai'e post-operatively in the percutaneous 
group in this series. Factors that may have contributed include reducing the surgical 
stress response, thereby influencing the severity of MODS, wliile simultaneously 
addressing the necrotic component and achieving adequate drainage, allowing 
sepsis to resolve. In addition, the detrimental effects on respiratory function and 
longer anaesthetic times associated with laparotomy are minimised with the 
percutaneous teclinique resulting in reduced respiratoiy impairment post- 
operatively.
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Pre-operative MODS
In keeping with other studies we found an association between the presence of 
persisting MODS pre-operatively and a higher mortality rate (23) higlilighting the 
difficulty in managing these severely ill patients. The type of proceduie performed 
did not have any impact on outcome in this group. It should be noted that the 
numbers are small and this study did not set out to look at patients with pre­
operative MODS and effect of procedure on outcome. Ideally this should be 
addressed by investigating a larger cohort of patients with pre-operative MODS.
Limitations of the study.
This retrospective review is a description of factors affecting outcome in patients 
undergoing two different procedures over a 13 year period. Although the patients 
were prospectively identified and data collected, they were not randomised to 
treatment and were not prospectively matched. In addition, various improvements 
in critical care such as the introduction of a High Dependency Unit may have 
affected patient outcome. Insufficient data regarding HDU stays was available for 
analysis. ITU stays were chosen as an indicator of MODS as it was more easily 
measurable in this group of patients and reflects severity of organ dysfunction 
appropriately. This study has shown that percutaneous necrosectomy is effective in 
the definitive surgical management of infected pancreatic necrosis. It facilitates 
drainage of necrotic fluid collections as well as effective debridement of solid 
necrotic tissue. It is less invasive than open necrosectomy which confers significant 
benefits in terms of minimising the inflammatory response to surgery, particularly 
in high-risk patients predisposed to MODS. In this series of patients, the mortality 
rate is similai* to conventional open necrosectomy. It would be hoped that in futui’e.
the reduction in bleeding complications would have a positive impact on reducing
Further randomised clinical trials would be helpful in identifying the optimal 
procedure for an individual patient and may contribute to lowered mortality rates.
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the mortality rate in patients undergoing percutaneous pancreatic necrosectomy. f
Chapter 4
Effect of Microbiology on outcome in Infected Pancreatic 
Necrosis
4.1 Introduction
4.1.1 Antibiotic treatment in Infected Pancreatic Necrosis
Current recommendations advise debridement and drainage as the optimal course of 
management of infected pancreas necrosis (39). The surgical management of 
infected pancreatic necrosis has been outlined previously. In addition to surgical 
drainage, patients are managed with additional anti-microbial therapy appropriate to 
the infecting organism(s) based on microbiology advice. The spectrum of antibiotic 
usage has changed in the last few decades for many infective conditions including 
infected pancreatic necrosis. Widespread usage of broad spectrum antibiotics for a 
wide variety of medical and surgical infections, both in hospitals and in the 
community, have altered their range of effectiveness and has been a factor in the 
development of resistant organisms (186, 187). In the last decade,methicillin- 
resistant Staph. Aui*eus (MRSA) has emerged as an aggressive, resistant gram- 
positive bacterium and is becoming increasingly prevalent, particularly in hospital 
patients who are immuno-compromised to some degree. The elderly post-operative 
patient is particularly at risk. The development of newer antimicrobial therapeutic 
agents in response to resistant infections allows more specific targeting of 
organisms. However some of these agents are more toxic than previous generations 
of drugs adding fuither complexity in patient management. The bacteriological 
spectrum of infected pancreatic necrosis is similar to intestinal fiora(149.
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Previously, broad spectrum antibiotics have been used to supplement surgical 
management of infected pancreatic necrosis with beneficial effects. Antibiotics 
penetrate the pancreas to varying extents and have differing efficacy against 
organisms involved in pancreatic infection. In a study of pancreatic antibiotic 
concentrations in necrotizing pancreatitis, Pefloxacin and metronidazole achieved 
good pancreatic excretion levels and exceeded the minimum inhibitory 
concentration (MIC) required for the majority of bacteria involved. Imipenem was 
slightly less effective(188). An efficacy factor has been applied to the majority of 
antibiotics used in pancreatic infections. This is based on type and frequency of 
infection, antibiotic tissue concentration and percentage of inliibited strains. A 
factor of 1 indicates complete inhibition of bacteria in infected pancreatic necrosis. 
(Table 4.1)
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Table 4.1: Antibiotic efficacy factors (adapted from (189))
Antibiotic class Aitibiotic Efficacy factor
Aminoglycosides Netilmicin 0.14
Tobramycin 0.12
Acylureidopenicillins Mezlocillin 0.71
Piperacillin 0.72
Cephalosporins Cefotiam 0.75
Ceftizoxime 0.76
Cefotaxime 0.78
Ceftriaxone 0.79
Quinolones Ciprofloxacin 0.86
Ofloxacin 0.87
Carbapenems Imipenem 0.98
Other studies have shown that tobramycin, netilmicin and ampicillin are less 
effective in pancreatic infection as they do not penetrate well into the pancreas 
(188,190).
4,1.2 Selective Gut decontamination
Bacterial translocation from the gut has been proposed as a possible source of 
pancreatic infection. Increased intestinal permeability may be due to splanchnic 
hypoperfusion and reperfusion injury. An association between gut barrier failuie 
and severity of illness has been demonstrated in AP patients (152). Selective 
decontamination reduces intestinal bacterial colonies by administration of non­
absorbable antibiotics. Previous studies using selective decontamination in ICU
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patients with sepsis have shown a reduction in Gram-negative septic complications.
However, no cleai’ reduction in mortality has been demonstrated (191). It has been 
proposed that by reducing pathogenic enteric bacteria, this may reduce microbial 
tianslocation and minimise pancreatic infection. Only one controlled trial has 
investigated prophylactic selective decontamination in acute pancreatitis. Although 
this trial demonstrated a reduction in pancreatic infection and mortality, a short 
dose of parenteral Cefmoxime was also administered making it difficult to interpret 
these outcomes in relation to selective gut decontamination alone (192). In an 
animal model of AP, selective decontamination of the gut by administration of 
early probiotic bacteria (Lactobacilli) reduced the incidence of pancreatic tissue and 
mesenteric lymph node colonisation with pathogenic bacteria (193).
4.1.3 Indications for antibiotic therapy
Patients with severe acute pancreatitis who have evidence of organ dysfunction but 
not of necrosis do not require antibiotic treatment. Conversely those with evidence 
of infected pancreatic necrosis will be commenced on antibiotic treatment for the 
duration of sepsis in addition to definitive surgical management. The antibiotics >|
given will depend on the bacteriological spectrum and antibiotic resistance.
Prolonged antibiotic therapy without sur gical drainage has been attempted in a few 
selected patients with some success but they invariably tended to have a milder 
clinical course without multiple organ dysfunction (52). In those with organ 
dysfunction and pancreatic necrosis, not proven to be infected, tire question of 
whether to give prophylactic antibiotics remains controversial.
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4.1.4 Clinical Controversy: Use of prophylactic antibiotics
The issue of whether to give patients early prophylactic antibiotics has been the 
subject of discussion for many yeai*s and consensus is yet to be reached.
In the 1970’s and early 1980’s, several small studies were published which did not 
support the use of prophylaxis (194,195). Antibiotics were given early on in the 
course of illness to patients with mild acute pancreatitis. No obvious differences in 
mortality or infection rates were observed. In one study, Ampicillin was used and 
as mentioned previously, this does not penetrate the pancreas. In addition, it is now 
well recognised that patients with mild AP are unlikely to have septic complications 
or to die from their illness tlierefore limiting any useful information that can be 
obtained from these studies. New evidence recommending prophylaxis came from 
an animal study which found ciprofloxacin superior to imipenem in reducing 
mortality in rats with initiated acute pancreatitis (196).More recently, four small 
randomised prospective trials in the early 1990’s were published with conflicting 
results. These focused on the use of prophylactic empirical antibiotics in high-risk 
patients and are discussed further below. In 1993, a multi-centre trial randomised 
41 patients to receive Imipenem early in the course of AP, compared to 33 controls 
with no antibiotics (197). All patients had pancreatic necrosis. This trial showed a 
reduction in pancreatic and non-pancreatic infection rates but this was not reflected 
in mortality rates. In 1995, a series of 60 patients were studied with 50% receiving 
prophylactic Cefuioxime and the others no initial antibiotics (198). Twenty-tliree of 
these 30 patients however required antibiotic tieatment for suspected infection at a 
later point. The patients in this study were recruited on the basis of either pancreatic 
necrosis and/ or a high CRP. Despite the heterogenecity of the patients, the 
mortality rates and septic complications were lower in the cefuroxime group. The
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most common pathogen cultured was Staph, epidermidis from pancreatic necrotic 
tissue or central venous lines, despite negative blood cultures, suggesting 
contamination from skin commensals. Interestingly, no difference in pancreatic 
infection rates was observed. A study published in the same year compared 
prophylactic selective decontamination (norfloxacin, colistin and amphotericin as a 
gum paste with IV cefotaxime) in 50 patients, with 52 patients who received no 
additional treatment. Significant reductions in both late mortality and pancreatic 
infection were noted (192). A smaller study published a year later comparing 
ceftazidime. Amikacin and mettonidazole with no prophylactic antibiotics in a total 
of 23 patients did not show any significant differences in mortality or pancreatic 
infection rates (174). These studies were reported as showing a decrease in 
infective complications. However as noted, on closer inspection, only two of these 
studies showed reduced pancreatic infection rates and only two showed a reduction 
in mortality rates. It is worth noting that the only study with a positive outcome for 
both mortality and pancreatic infection is the trial primarily aimed at selective 
decontamination of the gut as the main criterion of treatment rather than a specific 
prophylactic course of antibiotics. The combined number of patients in the 
antibiotic groups is 132. This number, considering the variety of agents used 
(including cefuroxime which doesn’t attain adequate pancreatic tissue 
concentrations) and the various treatment protocols in different centres, is 
considered small. Despite this, the premise that prophylactic antibiotics were 
beneficial in preventing pancreatic infection, and in particular infected necrosis, led 
to widespread use of prophylactic antibiotics in patients with severe AP and in 
particular, those with sterile necrosis.
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To further investigate the potential benefit of different prophylactic antibiotics.
Bas si compared imipenem to pefloxacin in a randomised, controlled, multi-centre 
trial comprising 60 patients with pancreatic necrosis of over 50% of the gland 
(199). Imipenem was more effective in reducing the incidence of infected 
pancreatic necrosis compared to pefloxacin (10%v34%, p<0.05). No difference in 
mortality rates was observed. Interestingly, those given imipenem who 
subsequently developed infected necrosis all died, additionally, in those given 
pefloxacin, there was a higher incidence of fungal infection associated with a 
poorer outcome. This trial, as with the previously discussed randomised trials, was 
not blinded. In 2001, Nordback compared the timhig of imipenem treatment in a 
randomised trial in patients with necrotising pancreatitis (200). Imipenem was 
given early to 25 patients. Late imipenem therapy was started upon reaching 
operative “criteria” (high CRP or WCC, positive pancreatic FNA) in 14 of 33 
patients without prior early imipenem treatment. Only two patients in the early 
group fulfilled operative criteria. Of the 14 patients in the late group, 9 responded to 
imipenem and did not require surgery. Less organ dysfunction was noted in the 
early imipenem group. Mortality rates were similar (8%vl5%, p^NS). The study 
reports a significantly reduced need for surgery in the early group. However, when 
those in the untreated group are given imipenem, the actual percentage of patients 
in each group who proceeded to surgery is similar (2/25 v 5/33, p=NS). This study 
therefore fails to show a reduction in the incidence of infected necrosis, mortality, 
or need for surgery.
Meropenem has been shown to have a similar profile to imipenem with regards to 
rates of pancreatic and extra-pancreatic infection, and outcome (201). Three meta­
analyses were performed on the use of prophylactic antibiotics. (55,202,203). Based
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on the evidence available up until then, they showed a reduction in mortality 
associated with the use of prophylactic antibiotics. Fui’thermore, the Coclu ane 
database review showed a reduction in super-infection of necrosis.
As a result of these studies, several guidelines were issued promoting the use of 
prophylactic antibiotics resulting in their widespread use(7). This occurred not only 
in severe cases but also in mild AP where no benefit has been shown. A survey of 
UK and Irish surgeons a year after the UK guidelines were published showed that 
88% prescribed prophylactic antibiotics, with 24% of respondents using 
prophylactic antibiotics in all cases of acute pancreatitis (204). More recently, the 
first double-blinded randomised control trial of prophylactic antibiotics in 
necrotising pancreatitis was performed (205). This compared ciprofloxacin and 
metronidazole in 56 patients versus placebo in 58 patients and did not show any 
differences in the development of infected pancreatic necrosis or mortality.
Recent lAP guidelines emphasise that no obvious reduction in mortality has been 
demonstrated by giving prophylactic antibiotics (39). Over the last decade, concern 
has been raised regarding the development of resistant organisms and an increase in 
fungal infection as a result of injudicious use of prophylactic antibiotics (206). It 
has been noted in several studies that patients with infected pancreatic necrosis 
have a worse outcome in the presence of Candida infection as a result of prolonged 
antibiotic therapy (56). The routine use of prophylactic antibiotics remains 
controversial. In patients with sterile necrosis there may be a role for prophylactic 
antibiotics in reducing the risk of infection, though any additional benefit conferred 
in terms of a reduction in operation and mortality rates has not been consistently 
demonstrated. Balanced against this, however, are the consequences of frequent
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prescribing of prophylactic antibiotics, as patients with resistant bacterial infection 
and fimgal colonisation have significantly worse outcomes.
Microbiology of infection in ÏPN
Bacterial colonisation of devitalised pancreatic tissue occurs in 40-70% of patients 
who develop pancreatic necrosis (207) and can be mono-microbial in up to 80% of 
cases (149). The spectrum of pancreatic infection is very similar to that seen in gut 
flora, lending evidence to the bacterial translocation hypothesis. This spectrum has 
changed in recent yeai's. Previously, gram-negative bacteria have been the most 
common pathogens isolated fiom necrotic pancreatic tissue, but there is increasing 
evidence to suggest that due to widespread use of prophylactic antibiotics in the 
1990’s, there has been a shift towards a higher prevalence of gram-positive bacteria 
and fungal organisms in pancreatic necrosis (50,208). Gram-positive infection has 
been associated with a higher mortality in one study of pancreatic necrosis (192). 
More recently, there have been several reports of an increased prevalence of 
antibiotic-resistant organisms.
4.1.5 Antibiotic resistant organisms
In 2004, De Waele et al found a high incidence of antibiotic-resistant organisms 
(52%) in IPN patients who had been given prophylactic antibiotics (55) but it 
should be noted that only 29% of these had primary infection of pancreatic necrosis 
with antibiotic-resistant organisms. Overall, those with resistant organisms required 
longer hospital stays and received longer antibiotic therapy. The mortality rate was 
slightly higher in these patients but not significantly so and no difference in MODS 
was noted.
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4.1.6 Fungal infection in IPN
Fungal growth in pancreatic necrosis has increased from approximately 10% in the 
early 1990’s up to 24% (50) in the new millennium. Studies which have described 
fungal pancreatic infection have had conflicting results in terms of the effect on 
mortality. Isenmann and Hoerauf both showed that fungal infection was associated 
with increased mortality (56,209). It should be noted however, that in Hoeraf s 
study, out of 7 patients with fungal infection who died, only 1 was treated with an 
appropriate anti-fungal.
Gloor did not demonstrate any difference in mortality in his study of 33 patients 
with IPN (50), Similarly, De Waele showed in a study of 46 IPN patients, that 
despite an incidence of 17% of primary and 22% of secondary fungal infection, 
there were no significant differences in mortality or severity of disease (210). 
Interestingly, there was a trend towards higher APACHE II scores in patients with 
fungal infection. The incidence of fungal infection seems to be rising and may be 
related to increasing prophylactic antibiotic use. Indiscriminate use of prophylactic 
antibiotics may predispose to fungal infection with an associated high mortality.
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4.2 Aims
To examine microbiological factors in relation to mortality in patients with infected 
pancreatic necrosis
1) To identify microbiological spectrum in patients with infected pancreatic 
necrosis tieated at Glasgow Royal Infirmaiy
2) To determine influence of prophylactic antibiotics on bacteriological 
spectrum and development of resistant organisms
3) To investigate relationship between resistant organisms and outcome.
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4.3 Methods
Patient details were collected retrospectively as described in Chapter 3 with similar 
inclusion and exclusion criteria.
Microbiology
Microbiology sampling included CT-guided FNA of areas of pancreatic necrosis 
pre-operatively, pancreatic tissue or fluid taken during the index necrosectomy 
procedui'e. Data on antibiotic and anti-fimgal usage was taken directly Jhom 
patient’s case-notes where available. Additional information was obtained from 
archived microbiology records.
Statistical analysis using SPSS9 was performed.
4.4 Results
All of the patients included in this study had evidence of infected pancreatic 
necrosis. The microbiology samples used included FNA of pancreatic necrosis pre- 
operatively or pancreatic tissue or fluid sampled intra-operatively.
4.4.1 Microbiology of Infected Pancreatic Necrosis
Ninety-nine patients with infected pancreatic necrosis treated surgically at Glasgow 
Royal Infirmary between Dec 1989 and March 2003 were included in this study. 
The incidence of individual infecting organisms is shown (Table 4.2). It outlines the 
relative proportion of gram-positive, gram-negative, anaerobic bacteria and fungi 
that were cultured in this group of patients.
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Table 4.2: Incidence of organisms isolated (no of patients)
Organism cultui'ed Total
Gram Negative Coliforms 33
Mixed faecal flora 4
Klebsiella 5
Pseudomonas 6
Proteus 2
Escherichia coli 4
Bacteroides 4
Clostridium 4
Gram Positive Staphlycoccus auieus 24
Streptococcus 16
Enterococcus 20
Anaerobes 7
Fungi 21
Fifty-seven patients had monomicrobial infection, 42 patients grew polymicrobial 
flora.
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Monomicrobial organisms
Ecoli (1.8%)
anaerobes (3 6%)
Fungi (14%) CoUforms (26 3%)
Proteus (1.8%)
nterococcus (8.8%)
Klebsiella (5.3%)
Pseudomonas (1.8%)
Streptococci (5 3%)
Staph aureus(31.6%)
Figure 4.1: Monomicrobial infection
This pie chart shows that coliforms (26.3%)and staphlycoccus aureus (31.6%) are 
the most common organisms cultured in patients with initial monomicrobiaal 
infection (Figure 4.1). Fungi were identified as the sole primary infecting agent in 
14% of patients.
4.4.2 Prophylactic Antibiotics
From 1989, some GRI patients had received prophylactic antibiotics prior to 
surgery for IPN. This was not conventional practice in the majority of referring 
hospitals until 1994. This practice has continued until the present day in many of 
the referring hospitals in the region. From 1998, early administration of 
prophylactic antibiotics to patients with severe AP has not been part of the standard 
treatment protocol for patients admitted directly to GRI with AP (Figure 4.2)
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Use of prophylactic antibiotics over time
IQ>CL D
Prophylaxis
H i  No antibiotics 
Antibiotics
1989/90 1992 1994 1996 1998 2000 2002/3
1991 1993 1995 1997 1999 2001
Admission year
Figure 4.2 Use of prophylactic antibiotics over time
This bar chart demonstrates the distribution over time of patients given prophylactic 
antibiotics. In 3 patients, information regarding the use of prophylaxis was 
unavailable and they have been excluded from this section of analysis.
Prophylactic antibiotics and referring hospital.
Further analysis of patients receiving prophylactic antibiotics after 1998 reveals that 
the majority of these patients have been admitted initially to other hospitals and 
subsequently transferred to GRI (Figure 4.3). Overall, only 12 of 29 (41%) GRI 
patients received prophylactic antibiotics compared to 45 of 67 (67%) referred 
patients (p=0.018)
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Figure 4.3: Prophylactic antibiotics and admitting hospital
Prophylactic antibiotics by institution
HOSPITAL
Other
I 0)CL
1989/90 1993 1995 1997 1999 2001
1992 1994 1996 1998 2000 2002/3
Year of admission
Since 1998, few patients admitted initially to GRI received prophylactic antibiotics 
compared to those referred from other centres. Interestingly, significantly less GRI 
admitted patients developed resistant infection compared to patients transferred 
from referring hospitals (p=0.028) (Table 4.3)
Table 4.3: Resistant organisms and admitting hospital
Infection GRI patients Referred patients Total
Bacteria alone 25 42 67
Fungi or MRSA 5 27 32
Total 30 69 99
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Prophylactic Antibiotics and Microbial Spectrum
Table 4.4 Microbial organisms 1989-2002
Admission
period
1989-
1993
1994-
1998
1998-
2002
Total p value
Patient 16 35 48 99
numbers
Organism Monomicrobial 50% 74% 52%
cultured (%)
Gram Coliforms 2 9 22 33 0.005
Negative
Mixed faecal 1 0 3 4
flora
Klebsiella 0 5 0 5
Pseudomonas 3 1 2 6
Proteus 1 1 0 2
Escherichia coli 2 0 1 4
Bacteroides 1 1 2 4
Clostridium 0 1 3 4
Gram Staphlycoccus 5 6 13 24
Positive aureus
Streptococcus 5 4 7 16
Enterococcus 0 4 16 20 0.006
Anaerobes 0 1 6 7
Fungi 4 11 6 21
* MRSA developed in 7 of these patients
Secondary Fungal Infection 2 2 1 5
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2 0 -
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Figure 4.4: Prophylactic antibiotics and resistant organisms
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Prophylactic Antibiotics and Microbial Spectrum
The study period was divided into 3 phases in relation to the use of prophylactic 
antibiotics. The microbial spectrum has changed slightly over the study period. 
Enterococci and coliforms became more prevalent in latter years. There was no 
significant difference in the prevalence of fungal infection with time. MRSA was 
recognised fi-om 1998. (Table 4.4)
The development of resistant organisms increased slightly over the time period but 
not significantly so. Although there is a similar appearance in the distribution of 
prophylactic antibiotics and resistant organisms over time (Figure 4.4), this 
represents a trend towaid significance but which is not reached. There was no 
association between the use of prophylactic antibiotics and the presence of resistant 
organisms in this group of patients. Data on the time from the start of prophylactic 
use until the procedure was available in 42 patients. In these patients there was no 
association between length of time from antibiotic commencement and resistant 
organisms.
Prophylaxis and Mortality
No association between antibiotic prophylaxis and mortality was demonstrated in 
this group of patients with infected pancreatic necrosis (Table 4.5).
Table 4.5: Mortality rates and antibiotic prophylaxis
n=patients 1989-1993 1994-1998 1999-2002 Total Deceased
Antibiotics 9(2) 23 (10) 25 (7) 57 19 (33%)
No antibiotics 5(0) 12(4) 22(5) 39 9 (23%)
(Number of patient deaths in brackets)
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4.4.3 Fimgal infection and outcome
Both primary and secondary fungal infection were significantly associated with a 
higher mortality rate (Table 4.6). The presence of MRSA was not associated with 
mortality.
Table 4.6 Fungal infection and outcome in patients with IPN
Type of infection Mortality P value
Survivors Deceased
Bacterial alone 57 17
Primary fungi 9 11 0.007
Secondary fungi 3 2 0.006
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4.5 Discussion 
Microbial Spectrum
The microbial spectrum has changed a little over the 12 years of the study with an 
increase in enterococci and coliforms. A shift from predominantly gram-negative to 
gi'am-positive organisms has been seen more recently in the United States but is not 
demonstrated in this group of IPN patients (208). As with this study, there was no 
significant change in the proportion of fungal infection.
Prophylactic Antibiotics
The use of prophylactic antibiotic use in patients either with MODS or sterile 
necrosis remains controversial. No clear-cut evidence has demonstrated a reduction 
in procedur es performed for IPN or a reduced mortality rate (39,205). In this 
institution, it was noted that there seemed to be a gr eater prevalence of antibiotic 
resistant organisms developmg between 1994-98 (Table 4.4). The greatest use of 
prophylactic antibiotics occurred during this period, as a result, the unit policy 
changed and GRI-admitted patients thereafter were not prescribed prophylactic 
antibiotics. There was a reduction in the number of ftingal infections seen after the 
change in policy, though when analysed in the context of total numbers, this is not 
significantly related to prophylactic antibiotic usage. Perhaps if this study was 
extended with larger patient numbers, the apparent trend towards significance in 
Figure 4.4 between use of prophylactic antibiotics and incidence of resistant 
organisms may be reached. It should be noted however, that the majority of referred 
patients still receive prophylactic antibiotics dvuing the early course of the illness.
In this gi’oup, tlie development of resistant organisms is significantly higher with an 
associated higher mortality rate. The duration of “prophylactic” antibiotic therapy is 
not clear from the data available for analysis but tliis may be a contributing factor to
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the development of resistant infection in the referred patients. Howard used 
antibiotics for 2 weeks only with no increased rate of fungal infection (208). 
Howard’s study also looked at the benefits of prophylactic fluconazole in patients 
with severe AP and while this was shown to reduce the mcidence of Candida 
species infection, the emergence of resistant fungal strains is a significant drawback 
and as such, routine anti-fungal prophylaxis could not be recommended.
Perhaps if patients do receive prophylaxis, it should be for a limited defined period 
unless there is evidence of infection. Future reduction of pathogenic flora by 
selective decontamination or probiotics may reduce bacterial translocation. 
However there may be a risk of further superinfection with multi-resistant 
organisms. This work has demonstrated a significant mortality rate in association 
with primary and secondary fungal contamination of IPN. This is a significant 
contributing factor to overall mortality and should be avoided if possible. This 
association is in keeping with previous studies which have demonstrated increased 
mortality rates in patients with fimgal infection (56,209).This observation may 
simply reflect an abnormal immune response in some patients, increasing their 
likelihood of death. This aspect has not been assessed in this study or demonstrated 
in previous studies. Future work could include a comparision of the immime 
response in IPN patients with and without fungal infection.
Chapter 5 Discussion
5.1 Acute Pancreatitis; What we know now
Much evidence has accumulated in the last twenty years regarding the underlying 
processes in the development of acute pancreatitis. Progress in molecular biology 
has increased awareness of acinar cell function and communication. Novel 
cytokines continue to be discovered increasing the body of knowledge on the role 
of cytokines in the development of local and systemic inflammation. The discovery 
of genetic variability in cytokine genes and subsequent effect on cytokine 
production gave rise to the hope that cytokine gene therapy may down-regulate 
excessive inflammatory activity and improve outcomes. Experimental studies in 
animals have shown promise in tliis area, but to date, no specific gene therapy or 
anti-cytokine agent has yet been shown to improve outcomes in patients with acute 
pancreatitis. Improved imaging modalities and increased availability including 
contrast enhanced CT, MRI and more recently, EUS, have improved pancreatic 
imaging, allowing earlier diagnosis in uncertain cases. Using these modalities, local 
pancreatic complications can be detected and managed definitively. Enteral 
nutrition reduces septic complications. ERCP and sphincterotomy in patients with 
cholangitis and jaundice improve outcomes in biliaiy pancreatitis. The 
incorporation of same admission/ early cholecystectomy into the management of 
AP reduces the risk of further, more severe attacks. Increased collective global 
experience in the management of patients with sterile and infected pancreatic 
necrosis has shown that surgical intervention should be reserved for those with IPN 
in association with MODS. Consensus meetings have defined some of the 
terminology used in association with acute pancreatitis, facilitating comparison 
between clinical trials and studies. National and international guidelines have been
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published, assisting clinicians in their management decisions based on recent 
evidence.
Despite these improvements, patients with MODS continue to die.
5.2 Why Do Patients Die?
The prime factor associated with mortality in acute pancreatitis is the development 
of organ dysfunction. Persistent MODS in early AP is associated with a mortality 
rate of over 50% and is a major determinant of survival (23). Up to 50% of all 
deaths occur within the first 1-2 weeks after admission, usually due to 
overwhelming MODS. The remainder of the deaths occur a few weeks after disease 
onset secondaiy to MODS, usually in association with infected pancreatic necrosis. 
The severity of the illness is dependant on multiple factors. Elderly and obese 
patients have a higher risk of death. This has been shown previously and in this 
series of IPN patients, is confirmed in elderly patients. The reason for this is 
probably related to pre-existing co-morbidity limiting resistance to the adverse 
effects of systemic inflammation resulting in MODS. From previous studies, tlie 
imderlying aetiology does not seem to contribute to the development of MODS. 
However the development of local complications does influence outcome. 
Pancreatic necrosis is associated with higher mortality rates than other local 
complications, but this again is due to a greater association between necrosis and 
MODS. The greater the extent of necrosis, the higher the risk of organ failure (46). 
Infected necrosis is more likely to drive MODS as a result of undrained sepsis 
regardless of the extent of necrosis. As a result these patients have the highest 
mortality rates. In this series, IPN was associated with a mortality rate of 30%.
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Although there seems to have been a relative reduction in mortality rates due to 
increasing incidence, the actual numbers of patients dying has changed little. 
Standardised mortality ratios have remained static for over 30 years (1). Deaths 
continue to occur despite maximal supportive therapy in specialist units. Although 
improvements in supportive therapy, surgical procedures and better clinical 
management may help in avoiding some deaths, it seems that a small selected group 
of patients are pre-detennined to develop MODS and as a result, some of these will 
die. A reasonable explanation for this is that individual cytokine gene variation 
affects cytokine production and regulation of the inflammatory response. However 
the evidence so far is patchy and an exact understanding of the underlymg 
mechanisms remains elusive.
5.3 Influence of cytokine gene polymorphisms
Cytokines are known to be amongst the principle mediators of local and systemic 
inflammation in acute pancreatitis (90). Polymorphisms in cytokine gene loci 
influence gene expression, transcription and production of various cytokines. 
Several gene polymorphisms have been associated with differential levels of 
cytokine production in patients with sepsis(211). The evidence regarding the 
relevance of cytokine gene polymorphisms affecting pancreatic disease severity is 
less clear. This study characterised interleukin-8 SNP frequencies in patients with 
acute pancreatitis in relation to severity and susceptibility. The results are in 
keeping with other studies of cytokine polymorphisms which did not show any 
positive associations between TNF and 11-1 gene polymorphisms and susceptibility 
or severity of AP (212) (120). All of these studies had patient numbers under 200, 
when these are divided into individual genotypic groups and severity of disease.
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small individual group numbers are likely to occur. For the less frequent genotypes, 
these are often in single figures. These studies do not conclusively exclude an 
association between cytokine polymorphisms and acute pancreatitis, yet they 
provoke more questions. Further studies into cytokine polymorphisms should be 
performed. However, it is often difficult to recruit enough patients who fit the 
inclusion criteria within a relatively short period. Multi-centre recruitment is a 
possible option but inlierent population differences may complicate the analysis and 
would need to be taken into account. With improvements in teclxnology such as 
micro-array sequencing, more polymorphisms could be tested in a shorter time 
frame. Prospective analysis of samples would avoid the problems encountered with 
historic stored samples. There may come a time when an individual patient’s 
unique genome is assessed on admission and treatment tailored to their individual 
genetic code, but that is still some time away.
5.4 Influence of Surgical Management
Infected pancreatic necrosis is a complication of AP associated with high mortality 
rates. Surgical debridement has been advocated previously in any patient with 
evidence of infected necrosis regardless of the presence of MODS (213). More 
recently, consensus guidelines recommend suigical treatment in patients with IPN 
associated with sepsis(39). Previously, radical resection procedures which removed 
healthy pancreatic tissue were associated with higher mortality rates (178) and are 
no longer recommended. There have been several modifications to surgical practice 
which have been associated with reduced mortality rates and fewer complications. 
The trend towards a less invasive approach continues. It is now recognised that a 
delay in sui'geiy allows demarcation of necrotic areas, limits tlie amount of
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debridement required and is associated with less bleeding complications. The 
optimal period for surgical debridement of necrosis is during the third or fouith 
week from onset, providing an opportunity for local inflammatory mediators to 
settle (93). In this study it has been shown that a minimally invasive necrosectomy 
procedure is associated with less post-operative MODS compared with the 
conventional open procedure. The percutaneous route was as successful in drainage 
and debridement of necrotic material when compared with the open procedure. 
However, the mortality rate was the same. There could be two reasons for this. 
Firstly, a gieater number of haemorrhagic complications occurred with the 
percutaneous technique compared with the open. This was more prevalent in the 
earlier years and these deaths may obscure a real reduction in mortality associated 
with the newer procedure. Secondly, there may be no effect on mortality  ^with the 
percutaneous procedure. Although the procedure is effective in minimising a 
“second hit” resulting from smgery, it is possible that these patients ai'e on the 
downward spiral of immunological dissonance and that the percutaneous procedure 
has less of a hastening effect when compared with the open one. This would 
certainly be in keeping with the longer hospital stays seen in percutaneous patients 
who died. Another study of a minimally invasive necrosectomy technique 
performed in Liverpool and developed in conjunction with the Glasgow group 
showed a similar reduction in post-operative MODS but no significant reduction in 
mortality (214). Time will tell if a reduction in bleeding complications in 
association with the percutaneous procedure will impact positively on reducing 
mortality. Currently all patients are managed by the percutaneous route unless there 
is a contra-indication (no access, intra-abdominal complication). It has not been 
possible to determine which patients are likely to benefit most fi'om the
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percutaneous procedure. It may be that younger, fitter patients with less MODS 
may be suitable for a definitive open necrosectomy, avoiding frequent re-operation 
and a longer hospital stay. The benefits of the percutaneous procedure include 
drainage of septic foci due to necrosis, minimising complications associated with 
laparotomy in addition to definitive surgical management of necrosis.
5.5 Influence of bacteriology.
The emergence of antibiotic-resistant organisms in the last 10-15 years in infected 
pancreatic necrosis can be attributed to the widespread use of prophylactic 
antibiotics (55). Although previously published international guidelines have 
advocated tlieir use in patients with severe acute pancreatitis (11,215), recent 
evidence in the form of a double-blind, randomised trial places this advice under 
question. The increase in fungal contamination of pancreatic necrosis with an 
associated higher mortality indicates that prophylactic antibiotics should be given 
with caution (199). Tliis series of patients with infected pancreatic necrosis 
represents a high-risk subgroup of all AP patients treated in this institution 
including tertiaiy referrals from other centres within the West of Scotland.
The bacteriological spectrum of infected pancreatic necrosis in this series of high- 
risk AP patients has changed little over the study period. MRS A has developed 
since 1998 but the overall proportion of gram-positive and gram-negative 
organisms is similar. The lack of a significant change in microbial spectrum may be 
due to the fact that not all the patients received prophylaxis. However, a greater 
number of fungi were noted in refeiTed patients who were also more likely to 
receive prophylaxis. The fact that they received prophylaxis is not surprising given 
the results of a UK wide survey indicating high levels of prescribing to patients
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with severe AP (204). It has been the unit’s policy in recent years not to 
indiscriminately prescribe antibiotics in the early course of the illness unless 
evidence of infection was obtained. The mortality rate in referred patients in this 
series tends toward significance, prophylactic antibiotic usage is higher and fungal 
infection more prevalent in this group, which could have been a factor influencing 
mortality. In this series, there was no association between receiving antibiotic 
prophylaxis and the development of resistant organisms except in the refeiTed 
patients. This may be related more to the dui ation of antibiotic “prophylaxis” than 
whether or not patients received antibiotics. Prophylactic antibiotic use in isolation 
was not found to be significantly associated with death, however, those who 
developed resistant infection in the form of MRS A or yeasts were at increased risk 
of mortality. Fungal infection alone or mixed with bacteria, whether at primaiy 
surgery or subsequently, was found to be a factor in increased mortality. Fungal 
infection can be seen as an indicator of severe disease as it is likely to occur* in 
patients who are immunocompromised. It is not the infecting organism per se that is 
aggressive, rather that the patient’s host defence system is unable to sustain 
adequate protection. Other studies have shown an increased mortality rate in 
patients with fungal infection (56,170). Some authors have proposed prophylactic 
anti-fungal treatment (210) but this may cause further super selection of resistant 
organisms in vulnerable patients. The debate regar ding the use of prophylactic 
antibiotics will continue. There is no evidence Ifom this study to state that 
prophylaxis contributes to mortality, however an increased prevalence of fungal 
organisms in referred patients may be due to prolonged antibiotic therapy.
It is possible that the avoidance of prophylactic antibiotics in patients admitted 
directly to GRI with AP in recent years has resulted in a lower incidence of fungal
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infection. It is clear that the prevalence of fungal infection is increasing in patients 
referred from centres outwith Glasgow Royal Infirmary since the routine 
introduction of prophylactic antibiotics. Based on the results in this series of 
patients with infected pancreatic necrosis, the policy of not prescribing prophylactic 
antibiotics is reasonable in order to minimise the development of resistant 
organisms with an associated higher mortality rate.
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5.6 Conclusion
In conclusion, this thesis aimed to explore factors affecting MODS and mortality in 
patients with severe acute pancreatitis. The pathophysiology of acute pancreatitis is 
not fully understood but it is becoming apparent that cytokine gene polymorphisms 
contribute to the development of the systemic inflammatory response.
This work has not demonstrated a significant association between interleukin-8 
polymorphisms and severity or susceptibility of AP. Less invasive surgical 
techniques reduce the incidence of MODS associated with surgical stress in patients 
with IPN but a subsequent beneficial effect on mortality has not yet been 
demonstrated. This may be due to pre-determined cytokine behaviour despite 
down-regulating the inflammatory response associated with IPN related sepsis, 
hi patients with IPN, the type of infection is important in determining outcome but 
this may reflect underlying immune/inflammatory activity rather than the virulence 
of a particular organism. Again this relates to an individual patient’s response to 
infection and inflammation and may also be due to inherent genetic factors.
From these three different aspects of acute pancreatitis, it can be seen that the 
development of MODS is central to outcome in acute pancreatitis and this process 
is driven by cytokine production and regulation. By exploring further the role that 
cytokines play in the development of MODS and the genetic influence of cytokine 
polymorphisms, a closer understanding of the pathophysiology of acute pancreatitis 
may be reached.
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5.7 Further Work
It is clear from this work that further investigation of cytokine gene polymorphisms 
should be carried out. Three further SNP’s have been discovered in the XL-8 
promoter region and these would make an ideal starting point. The continuing 
development of technology in parallel with the understanding of disease 
progression will allow faster analysis of a greater number of cytokines and 
potentially could occur during a patients admission.
Further work should include a randomised trial of minimally invasive and open 
necrosectomy techniques. The percutaneous procedure offers promising results 
with a potentially reduced mortality. If this is the case, it will then become 
important to identify which type of procedure is best suited to which patient. 
Further trials are needed to investigate the role of prophylactic antibiotics in 
patients with severe AP. They may have a role in preventing infection in some 
patients but can be associated with resistant organisms and higher mortality. If they 
are found to be beneficial then the optimal duration of use and the ideal antibiotic 
agents need to be identified.
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Appendix 1 RANSON Score
On admission to hospital
Serum Glucose >10mmol/l
WCC > 16x io7i
AST or ALT>250iu/l
orLDH>350iu/l
Within 48 hours
Haematocrit decrease by >10%
Urea increase > 0.7mmol/l
Serum Ca^  ^>2mmol/l
Fluid sequestration > 6 litres
PaOz <8KPa
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Appendix 2 Modified GLASGOW Score
Within 48 hours
AST/ALT>200iu/l
WCC> 15x 10^ /1
LDH > eOOiu/l
Albumin <32g/l
Serum Glucose >10mmol/l
Serum Ca2+ < 2mmol/l
Urea > 16mmol/l
Pa02 <60 mmHg (SkPa)
CRP >150
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